Proactiveinvestors USA & Canada Summit Therapeutics PLC https://www.proactiveinvestors.com Proactiveinvestors USA & Canada Summit Therapeutics PLC RSS feed en Wed, 16 Oct 2019 21:46:49 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) Summit eyes bright future for Ridinilazole https://www.proactiveinvestors.com/companies/news/904680/summit-eyes-bright-future-for-ridinilazole-904680.html Fri, 11 Oct 2019 15:18:00 -0400 https://www.proactiveinvestors.com/companies/news/904680/summit-eyes-bright-future-for-ridinilazole-904680.html Summit Therapeutics antibiotic leaves gut healthy but kills C.difficile https://www.proactiveinvestors.com/companies/news/904296/summit-therapeutics-antibiotic-leaves-gut-healthy-but-kills-cdifficile-904296.html Mon, 07 Oct 2019 14:24:00 -0400 https://www.proactiveinvestors.com/companies/news/904296/summit-therapeutics-antibiotic-leaves-gut-healthy-but-kills-cdifficile-904296.html Summit Therapeutics shares rise on phase II c.difficile data https://www.proactiveinvestors.com/companies/news/904100/summit-therapeutics-shares-rise-on-phase-ii-cdifficile-data-904100.html Thu, 03 Oct 2019 11:52:00 -0400 https://www.proactiveinvestors.com/companies/news/904100/summit-therapeutics-shares-rise-on-phase-ii-cdifficile-data-904100.html Summit presents DDS-04 data at antibiotic resistance conference https://www.proactiveinvestors.com/companies/news/902119/summit-presents-dds-04-data-at-antibiotic-resistance-conference-902119.html Thu, 05 Sep 2019 12:33:00 -0400 https://www.proactiveinvestors.com/companies/news/902119/summit-presents-dds-04-data-at-antibiotic-resistance-conference-902119.html Summit Therapeutics flags potential of new antibiotic to treat drug-resistant gonorrhoea https://www.proactiveinvestors.com/companies/news/224070/summit-therapeutics-flags-potential-of-new-antibiotic-to-treat-drug-resistant-gonorrhoea-224070.html Wed, 17 Jul 2019 11:59:00 -0400 https://www.proactiveinvestors.com/companies/news/224070/summit-therapeutics-flags-potential-of-new-antibiotic-to-treat-drug-resistant-gonorrhoea-224070.html Latest data shows potential of Summit Therapeutics' DDS-04 antibiotic to treat pneumonia and sepsis https://www.proactiveinvestors.com/companies/news/223597/latest-data-shows-potential-of-summit-therapeutics--dds-04-antibiotic-to-treat-pneumonia-and-sepsis-223597.html Tue, 09 Jul 2019 12:05:00 -0400 https://www.proactiveinvestors.com/companies/news/223597/latest-data-shows-potential-of-summit-therapeutics--dds-04-antibiotic-to-treat-pneumonia-and-sepsis-223597.html Summit Therapeutics in line to receive funding of up to US$64mln from US government https://www.proactiveinvestors.com/companies/news/222332/summit-therapeutics-in-line-to-receive-funding-of-up-to-us64mln-from-us-government-222332.html Tue, 18 Jun 2019 12:00:00 -0400 https://www.proactiveinvestors.com/companies/news/222332/summit-therapeutics-in-line-to-receive-funding-of-up-to-us64mln-from-us-government-222332.html Summit Therapeutics 'taking leadership role' in development of new antibiotics https://www.proactiveinvestors.com/companies/news/313726/summit-therapeutics--taking-leadership-role--in-development-of-new-antibiotics-13726.html Thu, 13 Jun 2019 12:49:00 -0400 https://www.proactiveinvestors.com/companies/news/313726/summit-therapeutics--taking-leadership-role--in-development-of-new-antibiotics-13726.html Summit Therapeutics reduces first quarter losses https://www.proactiveinvestors.com/companies/news/221977/summit-therapeutics-reduces-first-quarter-losses-221977.html Wed, 12 Jun 2019 12:13:00 -0400 https://www.proactiveinvestors.com/companies/news/221977/summit-therapeutics-reduces-first-quarter-losses-221977.html Summit Therapeutics well placed in the race to find next-generation antibiotic https://www.proactiveinvestors.com/companies/news/218703/summit-therapeutics-well-placed-in-the-race-to-find-next-generation-antibiotic-218703.html Tue, 16 Apr 2019 13:49:00 -0400 https://www.proactiveinvestors.com/companies/news/218703/summit-therapeutics-well-placed-in-the-race-to-find-next-generation-antibiotic-218703.html Summit Therapeutics soars as it hails potential of very early stage antibiotic https://www.proactiveinvestors.com/companies/news/218551/summit-therapeutics-soars-as-it-hails-potential-of-very-early-stage-antibiotic-218551.html Mon, 15 Apr 2019 11:40:00 -0400 https://www.proactiveinvestors.com/companies/news/218551/summit-therapeutics-soars-as-it-hails-potential-of-very-early-stage-antibiotic-218551.html Summit Therapeutics expands drug pipeline with antibiotics targeting deadly bacteria https://www.proactiveinvestors.com/companies/news/217864/summit-therapeutics-expands-drug-pipeline-with-antibiotics-targeting-deadly-bacteria-217864.html Wed, 03 Apr 2019 11:22:00 -0400 https://www.proactiveinvestors.com/companies/news/217864/summit-therapeutics-expands-drug-pipeline-with-antibiotics-targeting-deadly-bacteria-217864.html Summit Therapeutics advancing its pipeline of innovative antibiotics https://www.proactiveinvestors.com/companies/news/312766/summit-therapeutics-advancing-its-pipeline-of-innovative-antibiotics-12766.html Thu, 28 Mar 2019 12:14:00 -0400 https://www.proactiveinvestors.com/companies/news/312766/summit-therapeutics-advancing-its-pipeline-of-innovative-antibiotics-12766.html Summit Therapeutics well backed for next phase of development https://www.proactiveinvestors.com/companies/news/217327/summit-therapeutics-well-backed-for-next-phase-of-development-217327.html Wed, 27 Mar 2019 11:54:00 -0400 https://www.proactiveinvestors.com/companies/news/217327/summit-therapeutics-well-backed-for-next-phase-of-development-217327.html Summit Therapeutics shows off potential of Discuva platform at Berlin conference https://www.proactiveinvestors.com/companies/news/216479/summit-therapeutics-shows-off-potential-of-discuva-platform-at-berlin-conference-216479.html Thu, 14 Mar 2019 12:15:00 -0400 https://www.proactiveinvestors.com/companies/news/216479/summit-therapeutics-shows-off-potential-of-discuva-platform-at-berlin-conference-216479.html Summit Therapeutics shoots higher as data shows SMT-57 antibiotic potent against diverse, global gonorrhoeae strains https://www.proactiveinvestors.com/companies/news/215227/summit-therapeutics-shoots-higher-as-data-shows-smt-57-antibiotic-potent-against-diverse-global-gonorrhoeae-strains-215227.html Mon, 25 Feb 2019 12:49:00 -0500 https://www.proactiveinvestors.com/companies/news/215227/summit-therapeutics-shoots-higher-as-data-shows-smt-57-antibiotic-potent-against-diverse-global-gonorrhoeae-strains-215227.html Bryan Garnier sets 155p fair value target on Summit Therapeutics, offering around 550% upside https://www.proactiveinvestors.com/companies/news/214894/bryan-garnier-sets-155p-fair-value-target-on-summit-therapeutics-offering-around-550-upside-214894.html Tue, 19 Feb 2019 14:33:00 -0500 https://www.proactiveinvestors.com/companies/news/214894/bryan-garnier-sets-155p-fair-value-target-on-summit-therapeutics-offering-around-550-upside-214894.html Summit Therapeutics says first patient dosed in global Phase 3 clinical trials for its precision oral antibiotic, ridinilazole https://www.proactiveinvestors.com/companies/news/214546/summit-therapeutics-says-first-patient-dosed-in-global-phase-3-clinical-trials-for-its-precision-oral-antibiotic-ridinilazole-214546.html Wed, 13 Feb 2019 12:14:00 -0500 https://www.proactiveinvestors.com/companies/news/214546/summit-therapeutics-says-first-patient-dosed-in-global-phase-3-clinical-trials-for-its-precision-oral-antibiotic-ridinilazole-214546.html Summit Therapeutics to begin Phase 3 studies of ridinilazol this quarter https://www.proactiveinvestors.com/companies/news/312162/summit-therapeutics-to-begin-phase-3-studies-of-ridinilazol-this-quarter-12162.html Mon, 11 Feb 2019 15:12:00 -0500 https://www.proactiveinvestors.com/companies/news/312162/summit-therapeutics-to-begin-phase-3-studies-of-ridinilazol-this-quarter-12162.html Summit Therapeutics welcomes investment from US billionaire ahead of busy Q1 https://www.proactiveinvestors.com/companies/news/311836/summit-therapeutics-welcomes-investment-from-us-billionaire-ahead-of-busy-q1-11836.html Mon, 14 Jan 2019 15:57:00 -0500 https://www.proactiveinvestors.com/companies/news/311836/summit-therapeutics-welcomes-investment-from-us-billionaire-ahead-of-busy-q1-11836.html Bob Duggan: Meet the US biotech billionaire taking a 49% stake in Summit https://www.proactiveinvestors.com/companies/news/211351/bob-duggan-meet-the-us-biotech-billionaire-taking-a-49-stake-in-summit-211351.html Mon, 17 Dec 2018 16:30:00 -0500 https://www.proactiveinvestors.com/companies/news/211351/bob-duggan-meet-the-us-biotech-billionaire-taking-a-49-stake-in-summit-211351.html Summit funded through to 2020 thanks to US$25mln investment from US biotech billionaire https://www.proactiveinvestors.com/companies/news/205338/summit-funded-through-to-2020-thanks-to-us25mln-investment-from-us-biotech-billionaire-205338.html Mon, 17 Dec 2018 12:00:00 -0500 https://www.proactiveinvestors.com/companies/news/205338/summit-funded-through-to-2020-thanks-to-us25mln-investment-from-us-biotech-billionaire-205338.html US billionaire Robert Duggan to invest US$25mln into Summit Therapeutics https://www.proactiveinvestors.com/companies/news/211298/us-billionaire-robert-duggan-to-invest-us25mln-into-summit-therapeutics-211298.html Mon, 17 Dec 2018 07:44:00 -0500 https://www.proactiveinvestors.com/companies/news/211298/us-billionaire-robert-duggan-to-invest-us25mln-into-summit-therapeutics-211298.html Summit well-funded as it gears up for ridinilazole phase III trial early next year https://www.proactiveinvestors.com/companies/news/210983/summit-well-funded-as-it-gears-up-for-ridinilazole-phase-iii-trial-early-next-year-210983.html Tue, 11 Dec 2018 13:36:00 -0500 https://www.proactiveinvestors.com/companies/news/210983/summit-well-funded-as-it-gears-up-for-ridinilazole-phase-iii-trial-early-next-year-210983.html Summit Therapeutics presents data on gonorrhoea treatment at London event https://www.proactiveinvestors.com/companies/news/209024/summit-therapeutics-presents-data-on-gonorrhoea-treatment-at-london-event-209024.html Mon, 12 Nov 2018 13:26:00 -0500 https://www.proactiveinvestors.com/companies/news/209024/summit-therapeutics-presents-data-on-gonorrhoea-treatment-at-london-event-209024.html Summit Therapeutics to present successful studies of ridinilazole at IDWeek https://www.proactiveinvestors.com/companies/news/206292/summit-therapeutics-to-present-successful-studies-of-ridinilazole-at-idweek-206292.html Wed, 03 Oct 2018 11:55:00 -0400 https://www.proactiveinvestors.com/companies/news/206292/summit-therapeutics-to-present-successful-studies-of-ridinilazole-at-idweek-206292.html Summit identifies possible new ways to treat hospital-acquired superbugs https://www.proactiveinvestors.com/companies/news/204340/summit-identifies-possible-new-ways-to-treat-hospital-acquired-superbugs-204340.html Thu, 06 Sep 2018 11:43:00 -0400 https://www.proactiveinvestors.com/companies/news/204340/summit-identifies-possible-new-ways-to-treat-hospital-acquired-superbugs-204340.html Summit Therapeutics to kick off gonorrhoeae trial next year https://www.proactiveinvestors.com/companies/news/204231/summit-therapeutics-to-kick-off-gonorrhoeae-trial-next-year-204231.html Wed, 05 Sep 2018 11:41:00 -0400 https://www.proactiveinvestors.com/companies/news/204231/summit-therapeutics-to-kick-off-gonorrhoeae-trial-next-year-204231.html Summit Therapeutics awarded additional US$12mln under contract with US BARDA https://www.proactiveinvestors.com/companies/news/203060/summit-therapeutics-awarded-additional-us12mln-under-contract-with-us-barda-203060.html Thu, 16 Aug 2018 11:17:00 -0400 https://www.proactiveinvestors.com/companies/news/203060/summit-therapeutics-awarded-additional-us12mln-under-contract-with-us-barda-203060.html Summit Therapeutics encouraged by performance of C.diff treatment in latest trial https://www.proactiveinvestors.com/companies/news/202181/summit-therapeutics-encouraged-by-performance-of-cdiff-treatment-in-latest-trial-202181.html Fri, 03 Aug 2018 10:30:00 -0400 https://www.proactiveinvestors.com/companies/news/202181/summit-therapeutics-encouraged-by-performance-of-cdiff-treatment-in-latest-trial-202181.html Summit Therapeutics sees a bright future for its antibiotics programmes https://www.proactiveinvestors.com/companies/news/309823/summit-therapeutics-sees-a-bright-future-for-its-antibiotics-programmes-9823.html Wed, 11 Jul 2018 13:09:00 -0400 https://www.proactiveinvestors.com/companies/news/309823/summit-therapeutics-sees-a-bright-future-for-its-antibiotics-programmes-9823.html Summit Therapeutics receives grant to further its development of a treatment for gonorrhoea https://www.proactiveinvestors.com/companies/news/200480/summit-therapeutics-receives-grant-to-further-its-development-of-a-treatment-for-gonorrhoea-200480.html Tue, 10 Jul 2018 11:37:00 -0400 https://www.proactiveinvestors.com/companies/news/200480/summit-therapeutics-receives-grant-to-further-its-development-of-a-treatment-for-gonorrhoea-200480.html Summit’s focus firmly on ridinilazole after DMD disappointment https://www.proactiveinvestors.com/companies/news/199691/summits-focus-firmly-on-ridinilazole-after-dmd-disappointment-199691.html Wed, 27 Jun 2018 12:54:00 -0400 https://www.proactiveinvestors.com/companies/news/199691/summits-focus-firmly-on-ridinilazole-after-dmd-disappointment-199691.html Summit Therapeutics says PhaseOut DMD clinical trial did not meet primary endpoint https://www.proactiveinvestors.com/companies/news/199681/summit-therapeutics-says-phaseout-dmd-clinical-trial-did-not-meet-primary-endpoint-199681.html Wed, 27 Jun 2018 11:25:00 -0400 https://www.proactiveinvestors.com/companies/news/199681/summit-therapeutics-says-phaseout-dmd-clinical-trial-did-not-meet-primary-endpoint-199681.html Summit Therapeutics unveils second series of compounds which could kill gonorrhoea bacteria https://www.proactiveinvestors.com/companies/news/198590/summit-therapeutics-unveils-second-series-of-compounds-which-could-kill-gonorrhoea-bacteria-198590.html Mon, 11 Jun 2018 07:40:00 -0400 https://www.proactiveinvestors.com/companies/news/198590/summit-therapeutics-unveils-second-series-of-compounds-which-could-kill-gonorrhoea-bacteria-198590.html Summit Therapeutics chief hails potential of drug that treats fatal childhood disease https://www.proactiveinvestors.com/companies/news/198276/summit-therapeutics-chief-hails-potential-of-drug-that-treats-fatal-childhood-disease-198276.html Tue, 05 Jun 2018 11:30:00 -0400 https://www.proactiveinvestors.com/companies/news/198276/summit-therapeutics-chief-hails-potential-of-drug-that-treats-fatal-childhood-disease-198276.html Summit Therapeutics discovers new potential antibiotics for gonorrhoea https://www.proactiveinvestors.com/companies/news/195563/summit-therapeutics-discovers-new-potential-antibiotics-for-gonorrhoea-195563.html Mon, 23 Apr 2018 11:52:00 -0400 https://www.proactiveinvestors.com/companies/news/195563/summit-therapeutics-discovers-new-potential-antibiotics-for-gonorrhoea-195563.html Summit Therapeutics boosted by new DMD drug analysis https://www.proactiveinvestors.com/companies/news/195472/summit-therapeutics-boosted-by-new-dmd-drug-analysis-195472.html Fri, 20 Apr 2018 11:49:00 -0400 https://www.proactiveinvestors.com/companies/news/195472/summit-therapeutics-boosted-by-new-dmd-drug-analysis-195472.html Summit Therapeutics accelerating preparatory activities for next DMD study https://www.proactiveinvestors.com/companies/news/309113/summit-therapeutics-accelerating-preparatory-activities-for-next-dmd-study-9113.html Thu, 19 Apr 2018 15:27:00 -0400 https://www.proactiveinvestors.com/companies/news/309113/summit-therapeutics-accelerating-preparatory-activities-for-next-dmd-study-9113.html Summit Therapeutics completes dosing of ezutromid in PhaseOut DMD clinical trial https://www.proactiveinvestors.com/companies/news/195368/summit-therapeutics-completes-dosing-of-ezutromid-in-phaseout-dmd-clinical-trial-195368.html Thu, 19 Apr 2018 11:49:00 -0400 https://www.proactiveinvestors.com/companies/news/195368/summit-therapeutics-completes-dosing-of-ezutromid-in-phaseout-dmd-clinical-trial-195368.html Summit Therapeutics boss hails "landmark year"; investors look to next milestone https://www.proactiveinvestors.com/companies/news/194744/summit-therapeutics-boss-hails-landmark-year-investors-look-to-next-milestone-194744.html Wed, 11 Apr 2018 11:33:00 -0400 https://www.proactiveinvestors.com/companies/news/194744/summit-therapeutics-boss-hails-landmark-year-investors-look-to-next-milestone-194744.html Riccardo Lowi discusses Summit Therapeutics https://www.proactiveinvestors.com/companies/news/330118/riccardo-lowi-discusses-summit-therapeutics-0118.html Tue, 03 Apr 2018 13:13:00 -0400 https://www.proactiveinvestors.com/companies/news/330118/riccardo-lowi-discusses-summit-therapeutics-0118.html Summit Therapeutics Plc - Stock Valuation Undemanding https://www.proactiveinvestors.com/companies/news/430599/summit-therapeutics-plc---stock-valuation-undemanding-430599.html Tue, 03 Apr 2018 11:24:00 -0400 https://www.proactiveinvestors.com/companies/news/430599/summit-therapeutics-plc---stock-valuation-undemanding-430599.html Summit Therapeutics raises around £15mln from placing to advance its treatment for Duchenne Muscular Dystrophy https://www.proactiveinvestors.com/companies/news/193847/summit-therapeutics-raises-around-15mln-from-placing-to-advance-its-treatment-for-duchenne-muscular-dystrophy-193847.html Tue, 27 Mar 2018 12:40:00 -0400 https://www.proactiveinvestors.com/companies/news/193847/summit-therapeutics-raises-around-15mln-from-placing-to-advance-its-treatment-for-duchenne-muscular-dystrophy-193847.html Summit Therapeutics presents poster on Phase Out DMD clinical trial https://www.proactiveinvestors.com/companies/news/193161/summit-therapeutics-presents-poster-on-phase-out-dmd-clinical-trial-193161.html Wed, 14 Mar 2018 12:22:00 -0400 https://www.proactiveinvestors.com/companies/news/193161/summit-therapeutics-presents-poster-on-phase-out-dmd-clinical-trial-193161.html Summit Therapeutics discovers new antibiotic compounds in fight against gonorrhoea https://www.proactiveinvestors.com/companies/news/193074/summit-therapeutics-discovers-new-antibiotic-compounds-in-fight-against-gonorrhoea-193074.html Tue, 13 Mar 2018 12:15:00 -0400 https://www.proactiveinvestors.com/companies/news/193074/summit-therapeutics-discovers-new-antibiotic-compounds-in-fight-against-gonorrhoea-193074.html Summit Therapeutics expands enrolment in Phase 2 PhaseOut DMD trial https://www.proactiveinvestors.com/companies/news/192765/summit-therapeutics-expands-enrolment-in-phase-2-phaseout-dmd-trial-192765.html Wed, 07 Mar 2018 12:51:00 -0500 https://www.proactiveinvestors.com/companies/news/192765/summit-therapeutics-expands-enrolment-in-phase-2-phaseout-dmd-trial-192765.html Summit Therapeutics shares jump as initial results of clinical trial for Duchenne muscular dystrophy treatment shows "further positive findings" https://www.proactiveinvestors.com/companies/news/192181/summit-therapeutics-shares-jump-as-initial-results-of-clinical-trial-for-duchenne-muscular-dystrophy-treatment-shows-further-positive-findings--192181.html Mon, 26 Feb 2018 12:57:00 -0500 https://www.proactiveinvestors.com/companies/news/192181/summit-therapeutics-shares-jump-as-initial-results-of-clinical-trial-for-duchenne-muscular-dystrophy-treatment-shows-further-positive-findings--192181.html Summit Therapeutics hugely excited after big DMD ‘breakthrough’ https://www.proactiveinvestors.com/companies/news/308671/summit-therapeutics-hugely-excited-after-big-dmd-breakthrough-8671.html Fri, 26 Jan 2018 13:30:00 -0500 https://www.proactiveinvestors.com/companies/news/308671/summit-therapeutics-hugely-excited-after-big-dmd-breakthrough-8671.html Red letter day for Summit Therapeutics after positive interim ezutromid results https://www.proactiveinvestors.com/companies/news/308665/red-letter-day-for-summit-therapeutics-after-positive-interim-ezutromid-results-8665.html Thu, 25 Jan 2018 16:05:00 -0500 https://www.proactiveinvestors.com/companies/news/308665/red-letter-day-for-summit-therapeutics-after-positive-interim-ezutromid-results-8665.html Summit Therapeutics shares jump on 'exciting' interim results of ezutromid study https://www.proactiveinvestors.com/companies/news/190634/summit-therapeutics-shares-jump-on-exciting-interim-results-of-ezutromid-study-190634.html Thu, 25 Jan 2018 15:00:00 -0500 https://www.proactiveinvestors.com/companies/news/190634/summit-therapeutics-shares-jump-on-exciting-interim-results-of-ezutromid-study-190634.html Summit confirms £10mln acquisition of antibiotics discovery group Discuva https://www.proactiveinvestors.com/companies/news/189284/summit-confirms-10mln-acquisition-of-antibiotics-discovery-group-discuva-189284.html Wed, 27 Dec 2017 08:28:00 -0500 https://www.proactiveinvestors.com/companies/news/189284/summit-confirms-10mln-acquisition-of-antibiotics-discovery-group-discuva-189284.html Summit Thereapeutics surges as it licenses the Latin American rights to its CDI candidate https://www.proactiveinvestors.com/companies/news/189154/summit-thereapeutics-surges-as-it-licenses-the-latin-american-rights-to-its-cdi-candidate-189154.html Thu, 21 Dec 2017 08:33:00 -0500 https://www.proactiveinvestors.com/companies/news/189154/summit-thereapeutics-surges-as-it-licenses-the-latin-american-rights-to-its-cdi-candidate-189154.html Summit Therapeutics reports quarterly revenue growth as it makes progress with clinical trials https://www.proactiveinvestors.com/companies/news/188334/summit-therapeutics-reports-quarterly-revenue-growth-as-it-makes-progress-with-clinical-trials-188334.html Wed, 06 Dec 2017 14:00:00 -0500 https://www.proactiveinvestors.com/companies/news/188334/summit-therapeutics-reports-quarterly-revenue-growth-as-it-makes-progress-with-clinical-trials-188334.html Summit Therapeutics completes initial dosing of Duchenne muscular dystrophy treatment in trial https://www.proactiveinvestors.com/companies/news/187517/summit-therapeutics-completes-initial-dosing-of-duchenne-muscular-dystrophy-treatment-in-trial-187517.html Mon, 20 Nov 2017 13:48:00 -0500 https://www.proactiveinvestors.com/companies/news/187517/summit-therapeutics-completes-initial-dosing-of-duchenne-muscular-dystrophy-treatment-in-trial-187517.html Summit Therapeutics to present pre-clinical data that reveals potential of DMD treatment https://www.proactiveinvestors.com/companies/news/187025/summit-therapeutics-to-present-pre-clinical-data-that-reveals-potential-of-dmd-treatment-187025.html Thu, 09 Nov 2017 14:09:00 -0500 https://www.proactiveinvestors.com/companies/news/187025/summit-therapeutics-to-present-pre-clinical-data-that-reveals-potential-of-dmd-treatment-187025.html Summit Therapeutics in a great position nearing the business end of its development https://www.proactiveinvestors.com/companies/news/308337/summit-therapeutics-in-a-great-position-nearing-the-business-end-of-its-development-8337.html Tue, 07 Nov 2017 12:32:00 -0500 https://www.proactiveinvestors.com/companies/news/308337/summit-therapeutics-in-a-great-position-nearing-the-business-end-of-its-development-8337.html Summit Therapeutics enters revenue sharing agreement with Wellcome Trust for ridinilazole https://www.proactiveinvestors.com/companies/news/186805/summit-therapeutics-enters-revenue-sharing-agreement-with-wellcome-trust-for-ridinilazole-186805.html Mon, 06 Nov 2017 14:00:00 -0500 https://www.proactiveinvestors.com/companies/news/186805/summit-therapeutics-enters-revenue-sharing-agreement-with-wellcome-trust-for-ridinilazole-186805.html Summit Therapeutics given lift by appearance at infectious diseases conference https://www.proactiveinvestors.com/companies/news/185273/summit-therapeutics-given-lift-by-appearance-at-infectious-diseases-conference-185273.html Mon, 09 Oct 2017 12:42:00 -0400 https://www.proactiveinvestors.com/companies/news/185273/summit-therapeutics-given-lift-by-appearance-at-infectious-diseases-conference-185273.html Summit Therapeutics shares DMD data https://www.proactiveinvestors.com/companies/news/185050/summit-therapeutics-shares-dmd-data-185050.html Wed, 04 Oct 2017 11:56:00 -0400 https://www.proactiveinvestors.com/companies/news/185050/summit-therapeutics-shares-dmd-data-185050.html Summit teams up with cTAP as it looks to accelerate development of its DMD drug https://www.proactiveinvestors.com/companies/news/184520/summit-teams-up-with-ctap-as-it-looks-to-accelerate-development-of-its-dmd-drug-184520.html Mon, 25 Sep 2017 14:57:00 -0400 https://www.proactiveinvestors.com/companies/news/184520/summit-teams-up-with-ctap-as-it-looks-to-accelerate-development-of-its-dmd-drug-184520.html Summit Therapeutics chief keeps his eyes on two big prizes https://www.proactiveinvestors.com/companies/news/184010/summit-therapeutics-chief-keeps-his-eyes-on-two-big-prizes-184010.html Thu, 14 Sep 2017 13:12:00 -0400 https://www.proactiveinvestors.com/companies/news/184010/summit-therapeutics-chief-keeps-his-eyes-on-two-big-prizes-184010.html Summit Therapeutics' US fundraiser should secure drug developer's long-term financial future https://www.proactiveinvestors.com/companies/news/183961/summit-therapeutics-us-fundraiser-should-secure-drug-developer-s-long-term-financial-future-183961.html Thu, 14 Sep 2017 06:36:00 -0400 https://www.proactiveinvestors.com/companies/news/183961/summit-therapeutics-us-fundraiser-should-secure-drug-developer-s-long-term-financial-future-183961.html Summit Therapeutics soars after securing funding from US government agency https://www.proactiveinvestors.com/companies/news/183758/summit-therapeutics-soars-after-securing-funding-from-us-government-agency-183758.html Mon, 11 Sep 2017 14:02:00 -0400 https://www.proactiveinvestors.com/companies/news/183758/summit-therapeutics-soars-after-securing-funding-from-us-government-agency-183758.html Summit Therapeutics antibiotic delivers encouraging clinical trial results https://www.proactiveinvestors.com/companies/news/183458/summit-therapeutics-antibiotic-delivers-encouraging-clinical-trial-results-183458.html Tue, 05 Sep 2017 11:43:00 -0400 https://www.proactiveinvestors.com/companies/news/183458/summit-therapeutics-antibiotic-delivers-encouraging-clinical-trial-results-183458.html Summit Therapeutics DMD trial underway; mulls funding options for c.diff trial https://www.proactiveinvestors.com/companies/news/183245/summit-therapeutics-dmd-trial-underway-mulls-funding-options-for-cdiff-trial-183245.html Thu, 31 Aug 2017 11:25:00 -0400 https://www.proactiveinvestors.com/companies/news/183245/summit-therapeutics-dmd-trial-underway-mulls-funding-options-for-cdiff-trial-183245.html Summit Therapeutics presents first data from reformulated DMD treatment https://www.proactiveinvestors.com/companies/news/179699/summit-therapeutics-presents-first-data-from-reformulated-dmd-treatment-179699.html Thu, 22 Jun 2017 14:46:00 -0400 https://www.proactiveinvestors.com/companies/news/179699/summit-therapeutics-presents-first-data-from-reformulated-dmd-treatment-179699.html Summit Therapeutics boss to speak at DMD conference https://www.proactiveinvestors.com/companies/news/179331/summit-therapeutics-boss-to-speak-at-dmd-conference-179331.html Thu, 15 Jun 2017 13:27:00 -0400 https://www.proactiveinvestors.com/companies/news/179331/summit-therapeutics-boss-to-speak-at-dmd-conference-179331.html Summit Therapeutics sees first quarter loss narrow after revenue boost from its first milestone payment https://www.proactiveinvestors.com/companies/news/179245/summit-therapeutics-sees-first-quarter-loss-narrow-after-revenue-boost-from-its-first-milestone-payment-179245.html Wed, 14 Jun 2017 13:11:00 -0400 https://www.proactiveinvestors.com/companies/news/179245/summit-therapeutics-sees-first-quarter-loss-narrow-after-revenue-boost-from-its-first-milestone-payment-179245.html Summit Therapeutics says new data on selective antibiotic shows potency for treatment of clostridium difficile infection https://www.proactiveinvestors.com/companies/news/178783/summit-therapeutics-says-new-data-on-selective-antibiotic-shows-potency-for-treatment-of-clostridium-difficile-infection-178783.html Mon, 05 Jun 2017 12:39:00 -0400 https://www.proactiveinvestors.com/companies/news/178783/summit-therapeutics-says-new-data-on-selective-antibiotic-shows-potency-for-treatment-of-clostridium-difficile-infection-178783.html Summit Therapeutics strengthens R&D team https://www.proactiveinvestors.com/companies/news/178203/summit-therapeutics-strengthens-rd-team-178203.html Tue, 23 May 2017 13:10:00 -0400 https://www.proactiveinvestors.com/companies/news/178203/summit-therapeutics-strengthens-rd-team-178203.html Summit Therapeutics ‘keeping up drug development pace’ following $22mln milestone payment https://www.proactiveinvestors.com/companies/news/307464/summit-therapeutics-keeping-up-drug-development-pace-following-22mln-milestone-payment-7464.html Tue, 16 May 2017 10:41:00 -0400 https://www.proactiveinvestors.com/companies/news/307464/summit-therapeutics-keeping-up-drug-development-pace-following-22mln-milestone-payment-7464.html Summit Therapeutics to receive US$22mln milestone payment as final patient enrols for DMD trial https://www.proactiveinvestors.com/companies/news/177800/summit-therapeutics-to-receive-us22mln-milestone-payment-as-final-patient-enrols-for-dmd-trial-177800.html Mon, 15 May 2017 17:59:00 -0400 https://www.proactiveinvestors.com/companies/news/177800/summit-therapeutics-to-receive-us22mln-milestone-payment-as-final-patient-enrols-for-dmd-trial-177800.html Publishing of Phase II ridinilazole study in Lancet 'a significant achievement' for Summit https://www.proactiveinvestors.com/companies/news/307376/publishing-of-phase-ii-ridinilazole-study-in-lancet-a-significant-achievement-for-summit-7376.html Tue, 02 May 2017 15:12:00 -0400 https://www.proactiveinvestors.com/companies/news/307376/publishing-of-phase-ii-ridinilazole-study-in-lancet-a-significant-achievement-for-summit-7376.html Summit Therapeutics results from clinical trial of new antibiotic showcased in prestigious medical journal https://www.proactiveinvestors.com/companies/news/177130/summit-therapeutics-results-from-clinical-trial-of-new-antibiotic-showcased-in-prestigious-medical-journal-177130.html Tue, 02 May 2017 06:29:00 -0400 https://www.proactiveinvestors.com/companies/news/177130/summit-therapeutics-results-from-clinical-trial-of-new-antibiotic-showcased-in-prestigious-medical-journal-177130.html Summit Therapeutics is cashed-up and looking forward to exciting year https://www.proactiveinvestors.com/companies/news/175612/summit-therapeutics-is-cashed-up-and-looking-forward-to-exciting-year-175612.html Wed, 29 Mar 2017 13:20:00 -0400 https://www.proactiveinvestors.com/companies/news/175612/summit-therapeutics-is-cashed-up-and-looking-forward-to-exciting-year-175612.html Summit rises as it presses on with extension of PhaseOut DMD trial https://www.proactiveinvestors.com/companies/news/175460/summit-rises-as-it-presses-on-with-extension-of-phaseout-dmd-trial-175460.html Mon, 27 Mar 2017 12:33:00 -0400 https://www.proactiveinvestors.com/companies/news/175460/summit-rises-as-it-presses-on-with-extension-of-phaseout-dmd-trial-175460.html Summit Therapeutics hails Rare Disease Day https://www.proactiveinvestors.com/companies/news/173931/summit-therapeutics-hails-rare-disease-day-173931.html Tue, 28 Feb 2017 14:23:00 -0500 https://www.proactiveinvestors.com/companies/news/173931/summit-therapeutics-hails-rare-disease-day-173931.html University of Oxford increases its stake in Summit Therapeutics https://www.proactiveinvestors.com/companies/news/173631/university-of-oxford-increases-its-stake-in-summit-therapeutics-173631.html Thu, 23 Feb 2017 15:02:00 -0500 https://www.proactiveinvestors.com/companies/news/173631/university-of-oxford-increases-its-stake-in-summit-therapeutics-173631.html Summit Therapeutics aiming to 'make a big impact' with new drug Ridinilazole https://www.proactiveinvestors.com/companies/news/306847/summit-therapeutics-aiming-to-make-a-big-impact-with-new-drug-ridinilazole-6847.html Thu, 02 Feb 2017 15:25:00 -0500 https://www.proactiveinvestors.com/companies/news/306847/summit-therapeutics-aiming-to-make-a-big-impact-with-new-drug-ridinilazole-6847.html Summit soars as it outlines phase III designs for its C. Diff treatment https://www.proactiveinvestors.com/companies/news/172501/summit-soars-as-it-outlines-phase-iii-designs-for-its-c-diff-treatment-172501.html Wed, 01 Feb 2017 12:32:00 -0500 https://www.proactiveinvestors.com/companies/news/172501/summit-soars-as-it-outlines-phase-iii-designs-for-its-c-diff-treatment-172501.html Summit Therapeutics hires new COO as it advances to late-stage trials https://www.proactiveinvestors.com/companies/news/171814/summit-therapeutics-hires-new-coo-as-it-advances-to-late-stage-trials-171814.html Wed, 18 Jan 2017 14:03:00 -0500 https://www.proactiveinvestors.com/companies/news/171814/summit-therapeutics-hires-new-coo-as-it-advances-to-late-stage-trials-171814.html Summit Therapeutics looking forward to productive 2017 https://www.proactiveinvestors.com/companies/news/170542/summit-therapeutics-looking-forward-to-productive-2017-170542.html Thu, 15 Dec 2016 13:11:00 -0500 https://www.proactiveinvestors.com/companies/news/170542/summit-therapeutics-looking-forward-to-productive-2017-170542.html Summit Therapeutics recruits for US leg of PhaseOut study https://www.proactiveinvestors.com/companies/news/169088/summit-therapeutics-recruits-for-us-leg-of-phaseout-study-169088.html Wed, 16 Nov 2016 14:36:00 -0500 https://www.proactiveinvestors.com/companies/news/169088/summit-therapeutics-recruits-for-us-leg-of-phaseout-study-169088.html Summit and Sarepta: The key questions answered https://www.proactiveinvestors.com/companies/news/167040/summit-and-sarepta-the-key-questions-answered-167040.html Sun, 09 Oct 2016 06:15:00 -0400 https://www.proactiveinvestors.com/companies/news/167040/summit-and-sarepta-the-key-questions-answered-167040.html Summit/ Sarepta deal “very encouraging” for DMD sufferers https://www.proactiveinvestors.com/companies/news/306139/summit-sarepta-deal-very-encouraging-for-dmd-sufferers-6139.html Fri, 07 Oct 2016 09:50:00 -0400 https://www.proactiveinvestors.com/companies/news/306139/summit-sarepta-deal-very-encouraging-for-dmd-sufferers-6139.html Summit Therapeutics shares shoot up 90% after it inks $522mln Sarepta deal https://www.proactiveinvestors.com/companies/news/166900/summit-therapeutics-shares-shoot-up-90-after-it-inks-522mln-sarepta-deal-166900.html Tue, 04 Oct 2016 15:15:00 -0400 https://www.proactiveinvestors.com/companies/news/166900/summit-therapeutics-shares-shoot-up-90-after-it-inks-522mln-sarepta-deal-166900.html Sarepta licenses DMD treatment from Summit https://www.proactiveinvestors.com/companies/news/166906/sarepta-licenses-dmd-treatment-from-summit-166906.html Tue, 04 Oct 2016 13:39:00 -0400 https://www.proactiveinvestors.com/companies/news/166906/sarepta-licenses-dmd-treatment-from-summit-166906.html Summit treatment nominated 'rare pediatric disease' https://www.proactiveinvestors.com/companies/news/166542/summit-treatment-nominated-rare-pediatric-disease--166542.html Tue, 27 Sep 2016 11:58:00 -0400 https://www.proactiveinvestors.com/companies/news/166542/summit-treatment-nominated-rare-pediatric-disease--166542.html Summit's DMD treatment granted US fast track status https://www.proactiveinvestors.com/companies/news/166456/summit-s-dmd-treatment-granted-us-fast-track-status-166456.html Mon, 26 Sep 2016 11:49:00 -0400 https://www.proactiveinvestors.com/companies/news/166456/summit-s-dmd-treatment-granted-us-fast-track-status-166456.html Summit Therapeutics highlights clinical progress https://www.proactiveinvestors.com/companies/news/163664/summit-therapeutics-highlights-clinical-progress-163664.html Thu, 08 Sep 2016 13:35:00 -0400 https://www.proactiveinvestors.com/companies/news/163664/summit-therapeutics-highlights-clinical-progress-163664.html Summit to include new DMD formulation in PhaseOut trial https://www.proactiveinvestors.com/companies/news/129163/ Tue, 09 Aug 2016 13:08:00 -0400 https://www.proactiveinvestors.com/companies/news/129163/ Summit Therapeutics to Present at Canaccord Genuity Growth conference https://www.proactiveinvestors.com/companies/news/129084/summit-therapeutics-to-present-at-canaccord-genuity-growth-conference-129084.html Fri, 05 Aug 2016 19:21:00 -0400 https://www.proactiveinvestors.com/companies/news/129084/summit-therapeutics-to-present-at-canaccord-genuity-growth-conference-129084.html Summit Therapeutics "can alter treatment paradigm" for CDI https://www.proactiveinvestors.com/companies/news/305168/summit-therapeutics-can-alter-treatment-paradigm-for-cdi-5168.html Tue, 21 Jun 2016 13:41:00 -0400 https://www.proactiveinvestors.com/companies/news/305168/summit-therapeutics-can-alter-treatment-paradigm-for-cdi-5168.html Summit uses more than gut instinct to prove C.diff antibiotic's worth https://www.proactiveinvestors.com/companies/news/127332/summit-uses-more-than-gut-instinct-to-prove-cdiff-antibiotic-s-worth-127332.html Tue, 21 Jun 2016 07:08:00 -0400 https://www.proactiveinvestors.com/companies/news/127332/summit-uses-more-than-gut-instinct-to-prove-cdiff-antibiotic-s-worth-127332.html Summit Therapeutics recruits first phase II DMD patient https://www.proactiveinvestors.com/companies/news/127253/summit-therapeutics-recruits-first-phase-ii-dmd-patient-127253.html Fri, 17 Jun 2016 13:01:00 -0400 https://www.proactiveinvestors.com/companies/news/127253/summit-therapeutics-recruits-first-phase-ii-dmd-patient-127253.html Summit Therapeutics to host New York DMD event https://www.proactiveinvestors.com/companies/news/126894/summit-therapeutics-to-host-new-york-dmd-event-126894.html Wed, 08 Jun 2016 13:09:00 -0400 https://www.proactiveinvestors.com/companies/news/126894/summit-therapeutics-to-host-new-york-dmd-event-126894.html Summit set to start dosing in DMD trial in second quarter https://www.proactiveinvestors.com/companies/news/126679/summit-set-to-start-dosing-in-dmd-trial-in-second-quarter-126679.html Thu, 02 Jun 2016 13:07:00 -0400 https://www.proactiveinvestors.com/companies/news/126679/summit-set-to-start-dosing-in-dmd-trial-in-second-quarter-126679.html Summit Therapeutics to present CDI antibiotic results https://www.proactiveinvestors.com/companies/news/126268/summit-therapeutics-to-present-cdi-antibiotic-results-126268.html Mon, 23 May 2016 13:26:00 -0400 https://www.proactiveinvestors.com/companies/news/126268/summit-therapeutics-to-present-cdi-antibiotic-results-126268.html Summit Therapeutics looks to pivotal year ahead with ezutromid and ridinilazole https://www.proactiveinvestors.com/companies/news/125750/summit-therapeutics-looks-to-pivotal-year-ahead-with-ezutromid-and-ridinilazole-125750.html Tue, 10 May 2016 12:20:00 -0400 https://www.proactiveinvestors.com/companies/news/125750/summit-therapeutics-looks-to-pivotal-year-ahead-with-ezutromid-and-ridinilazole-125750.html Summit Therapeutics PLC boosted by US patent for C-diff antibiotic https://www.proactiveinvestors.com/companies/news/125364/summit-therapeutics-plc-boosted-by-us-patent-for-c-diff-antibiotic-125364.html Thu, 28 Apr 2016 12:25:00 -0400 https://www.proactiveinvestors.com/companies/news/125364/summit-therapeutics-plc-boosted-by-us-patent-for-c-diff-antibiotic-125364.html Summit provides renewed hope for sufferers of muscle wasting disease https://www.proactiveinvestors.com/companies/news/125263/summit-provides-renewed-hope-for-sufferers-of-muscle-wasting-disease-125263.html Tue, 26 Apr 2016 15:45:00 -0400 https://www.proactiveinvestors.com/companies/news/125263/summit-provides-renewed-hope-for-sufferers-of-muscle-wasting-disease-125263.html Summit Therapeutics passes “important milestone” with FDA approval https://www.proactiveinvestors.com/companies/news/304953/summit-therapeutics-passes-important-milestone-with-fda-approval-4953.html Tue, 26 Apr 2016 14:26:00 -0400 https://www.proactiveinvestors.com/companies/news/304953/summit-therapeutics-passes-important-milestone-with-fda-approval-4953.html FDA clears Summit Therapeutics to extend PhaseOut DMD trial to the US https://www.proactiveinvestors.com/companies/news/125238/fda-clears-summit-therapeutics-to-extend-phaseout-dmd-trial-to-the-us-125238.html Tue, 26 Apr 2016 11:46:00 -0400 https://www.proactiveinvestors.com/companies/news/125238/fda-clears-summit-therapeutics-to-extend-phaseout-dmd-trial-to-the-us-125238.html CEO: Summit Therapeutics’ ridinilazole generating “huge interest” from industry experts https://www.proactiveinvestors.com/companies/news/304880/ceo-summit-therapeutics-ridinilazole-generating-huge-interest-from-industry-experts-4880.html Tue, 12 Apr 2016 14:00:00 -0400 https://www.proactiveinvestors.com/companies/news/304880/ceo-summit-therapeutics-ridinilazole-generating-huge-interest-from-industry-experts-4880.html Summit Therapeutics PLC presents positive CDI results https://www.proactiveinvestors.com/companies/news/124614/summit-therapeutics-plc-presents-positive-cdi-results-124614.html Mon, 11 Apr 2016 14:57:00 -0400 https://www.proactiveinvestors.com/companies/news/124614/summit-therapeutics-plc-presents-positive-cdi-results-124614.html Summit Therapeutics PLC to present at Annual Healthcare Conference https://www.proactiveinvestors.com/companies/news/124509/summit-therapeutics-plc-to-present-at-annual-healthcare-conference-124509.html Wed, 06 Apr 2016 15:44:00 -0400 https://www.proactiveinvestors.com/companies/news/124509/summit-therapeutics-plc-to-present-at-annual-healthcare-conference-124509.html Summit Therapeutics advances muscular dystrophy drug https://www.proactiveinvestors.com/companies/news/124212/summit-therapeutics-advances-muscular-dystrophy-drug-124212.html Wed, 30 Mar 2016 12:35:00 -0400 https://www.proactiveinvestors.com/companies/news/124212/summit-therapeutics-advances-muscular-dystrophy-drug-124212.html Summit Therapeutics to present further data showing ridinilazole's superiority https://www.proactiveinvestors.com/companies/news/124160/summit-therapeutics-to-present-further-data-showing-ridinilazole-s-superiority-124160.html Tue, 29 Mar 2016 14:29:00 -0400 https://www.proactiveinvestors.com/companies/news/124160/summit-therapeutics-to-present-further-data-showing-ridinilazole-s-superiority-124160.html Summit Therapeutics' study identifies DMD biomarkers https://www.proactiveinvestors.com/companies/news/123693/summit-therapeutics-study-identifies-dmd-biomarkers-123693.html Tue, 15 Mar 2016 13:22:00 -0400 https://www.proactiveinvestors.com/companies/news/123693/summit-therapeutics-study-identifies-dmd-biomarkers-123693.html Summit Therapeutics PLC “optimist for the future” after latest ridinilazole phase II trial data https://www.proactiveinvestors.com/companies/news/304741/summit-therapeutics-plc-optimist-for-the-future-after-latest-ridinilazole-phase-ii-trial-data-4741.html Tue, 08 Mar 2016 13:28:00 -0500 https://www.proactiveinvestors.com/companies/news/304741/summit-therapeutics-plc-optimist-for-the-future-after-latest-ridinilazole-phase-ii-trial-data-4741.html Summit Therapeutics PLC's ridinilazole results continue to impress https://www.proactiveinvestors.com/companies/news/123369/summit-therapeutics-plc-s-ridinilazole-results-continue-to-impress-123369.html Mon, 07 Mar 2016 14:17:00 -0500 https://www.proactiveinvestors.com/companies/news/123369/summit-therapeutics-plc-s-ridinilazole-results-continue-to-impress-123369.html Summit Therapeutics' 'outstanding' C.difficile data published in major journal https://www.proactiveinvestors.com/companies/news/122923/summit-therapeutics-outstanding-cdifficile-data-published-in-major-journal-122923.html Wed, 24 Feb 2016 12:33:00 -0500 https://www.proactiveinvestors.com/companies/news/122923/summit-therapeutics-outstanding-cdifficile-data-published-in-major-journal-122923.html Summit Therapeutics gets nod for 'PhaseOut DMD' trial https://www.proactiveinvestors.com/companies/news/121604/summit-therapeutics-gets-nod-for-phaseout-dmd-trial-121604.html Thu, 21 Jan 2016 12:45:00 -0500 https://www.proactiveinvestors.com/companies/news/121604/summit-therapeutics-gets-nod-for-phaseout-dmd-trial-121604.html Summit’s CDI hails “key” patent win in Europe https://www.proactiveinvestors.com/companies/news/304565/summits-cdi-hails-key-patent-win-in-europe-4565.html Wed, 20 Jan 2016 08:22:00 -0500 https://www.proactiveinvestors.com/companies/news/304565/summits-cdi-hails-key-patent-win-in-europe-4565.html Summit Therapeutics awarded European patent for C.Difficile treatment https://www.proactiveinvestors.com/companies/news/121491/summit-therapeutics-awarded-european-patent-for-cdifficile-treatment-121491.html Tue, 19 Jan 2016 12:46:00 -0500 https://www.proactiveinvestors.com/companies/news/121491/summit-therapeutics-awarded-european-patent-for-cdifficile-treatment-121491.html Summit Therapeutics readies for two advanced trials https://www.proactiveinvestors.com/companies/news/120595/summit-therapeutics-readies-for-two-advanced-trials-120595.html Thu, 17 Dec 2015 12:19:00 -0500 https://www.proactiveinvestors.com/companies/news/120595/summit-therapeutics-readies-for-two-advanced-trials-120595.html Summit Therapeutics taking part in DMD forum https://www.proactiveinvestors.com/companies/news/120308/summit-therapeutics-taking-part-in-dmd-forum-120308.html Thu, 10 Dec 2015 14:18:00 -0500 https://www.proactiveinvestors.com/companies/news/120308/summit-therapeutics-taking-part-in-dmd-forum-120308.html Summit's alliance with Oxford Uni passes DMD milestone https://www.proactiveinvestors.com/companies/news/119959/summit-s-alliance-with-oxford-uni-passes-dmd-milestone-119959.html Wed, 02 Dec 2015 12:52:00 -0500 https://www.proactiveinvestors.com/companies/news/119959/summit-s-alliance-with-oxford-uni-passes-dmd-milestone-119959.html Summit's CDI trial results exceed expectations https://www.proactiveinvestors.com/companies/news/304403/summit-s-cdi-trial-results-exceed-expectations-4403.html Tue, 24 Nov 2015 14:45:00 -0500 https://www.proactiveinvestors.com/companies/news/304403/summit-s-cdi-trial-results-exceed-expectations-4403.html Summit soars on 'outstanding' C.difficile trial result https://www.proactiveinvestors.com/companies/news/119573/summit-soars-on-outstanding-cdifficile-trial-result-119573.html Mon, 23 Nov 2015 14:44:00 -0500 https://www.proactiveinvestors.com/companies/news/119573/summit-soars-on-outstanding-cdifficile-trial-result-119573.html Summit Therapeutics edging towards huge 'inflection point' https://www.proactiveinvestors.com/companies/news/119300/summit-therapeutics-edging-towards-huge-inflection-point--119300.html Tue, 17 Nov 2015 13:28:00 -0500 https://www.proactiveinvestors.com/companies/news/119300/summit-therapeutics-edging-towards-huge-inflection-point--119300.html Summit Therapeutics inks research extension with Oxford University https://www.proactiveinvestors.com/companies/news/119296/summit-therapeutics-inks-research-extension-with-oxford-university-119296.html Tue, 17 Nov 2015 13:17:00 -0500 https://www.proactiveinvestors.com/companies/news/119296/summit-therapeutics-inks-research-extension-with-oxford-university-119296.html Summit Therapeutics gearing up for "crunch" DMD trial https://www.proactiveinvestors.com/companies/news/119291/summit-therapeutics-gearing-up-for-crunch-dmd-trial-119291.html Tue, 17 Nov 2015 12:25:00 -0500 https://www.proactiveinvestors.com/companies/news/119291/summit-therapeutics-gearing-up-for-crunch-dmd-trial-119291.html Summit Therapeutics details the potential of key drug https://www.proactiveinvestors.com/companies/news/111309/summit-therapeutics-details-the-potential-of-key-drug-111309.html Wed, 30 Sep 2015 12:09:00 -0400 https://www.proactiveinvestors.com/companies/news/111309/summit-therapeutics-details-the-potential-of-key-drug-111309.html Summit Therapeutics to present additional data at key muscle conference https://www.proactiveinvestors.com/companies/news/111106/summit-therapeutics-to-present-additional-data-at-key-muscle-conference-111106.html Thu, 24 Sep 2015 12:30:00 -0400 https://www.proactiveinvestors.com/companies/news/111106/summit-therapeutics-to-present-additional-data-at-key-muscle-conference-111106.html Summit’s pre-clinical data reinforces antibiotic’s potential https://www.proactiveinvestors.com/companies/news/110975/summits-pre-clinical-data-reinforces-antibiotics-potential-110975.html Mon, 21 Sep 2015 14:08:00 -0400 https://www.proactiveinvestors.com/companies/news/110975/summits-pre-clinical-data-reinforces-antibiotics-potential-110975.html Summit Therapeutics reveals further positive results https://www.proactiveinvestors.com/companies/news/110924/summit-therapeutics-reveals-further-positive-results-110924.html Fri, 18 Sep 2015 13:32:00 -0400 https://www.proactiveinvestors.com/companies/news/110924/summit-therapeutics-reveals-further-positive-results-110924.html Summit Therapeutics successfully completes patient enrolment https://www.proactiveinvestors.com/companies/news/110691/summit-therapeutics-successfully-completes-patient-enrolment-110691.html Thu, 10 Sep 2015 12:28:00 -0400 https://www.proactiveinvestors.com/companies/news/110691/summit-therapeutics-successfully-completes-patient-enrolment-110691.html Summit CEO: Data results could be transformational for us https://www.proactiveinvestors.com/companies/news/304105/summit-ceo-data-results-could-be-transformational-for-us-4105.html Thu, 03 Sep 2015 15:38:00 -0400 https://www.proactiveinvestors.com/companies/news/304105/summit-ceo-data-results-could-be-transformational-for-us-4105.html Summit hires chief medical officer at "exciting time" https://www.proactiveinvestors.com/companies/news/110467/summit-hires-chief-medical-officer-at-exciting-time--110467.html Wed, 02 Sep 2015 12:15:00 -0400 https://www.proactiveinvestors.com/companies/news/110467/summit-hires-chief-medical-officer-at-exciting-time--110467.html Summit Therapeutics excited about clinical progress https://www.proactiveinvestors.com/companies/news/110348/summit-therapeutics-excited-about-clinical-progress-110348.html Thu, 27 Aug 2015 12:16:00 -0400 https://www.proactiveinvestors.com/companies/news/110348/summit-therapeutics-excited-about-clinical-progress-110348.html Summit advances as DMD drug moves to next phase https://www.proactiveinvestors.com/companies/news/110014/summit-advances-as-dmd-drug-moves-to-next-phase-110014.html Mon, 17 Aug 2015 14:52:00 -0400 https://www.proactiveinvestors.com/companies/news/110014/summit-advances-as-dmd-drug-moves-to-next-phase-110014.html UPDATE - Summit Therapeutics shares rise as biotech moves into "a data rich period" https://www.proactiveinvestors.com/companies/news/108987/update-summit-therapeutics-shares-rise-as-biotech-moves-into-a-data-rich-period--108987.html Tue, 14 Jul 2015 14:12:00 -0400 https://www.proactiveinvestors.com/companies/news/108987/update-summit-therapeutics-shares-rise-as-biotech-moves-into-a-data-rich-period--108987.html Summit Therapeutics' DMD potential highlighted by study https://www.proactiveinvestors.com/companies/news/108936/summit-therapeutics-dmd-potential-highlighted-by-study-108936.html Mon, 13 Jul 2015 13:11:00 -0400 https://www.proactiveinvestors.com/companies/news/108936/summit-therapeutics-dmd-potential-highlighted-by-study-108936.html Summit granted US fast track for superbug treatment https://www.proactiveinvestors.com/companies/news/108802/summit-granted-us-fast-track-for-superbug-treatment-108802.html Wed, 08 Jul 2015 12:11:00 -0400 https://www.proactiveinvestors.com/companies/news/108802/summit-granted-us-fast-track-for-superbug-treatment-108802.html Summit Therapeutics adds Europe to patent list for key compound https://www.proactiveinvestors.com/companies/news/108765/summit-therapeutics-adds-europe-to-patent-list-for-key-compound-108765.html Tue, 07 Jul 2015 13:04:00 -0400 https://www.proactiveinvestors.com/companies/news/108765/summit-therapeutics-adds-europe-to-patent-list-for-key-compound-108765.html Summit Therapeutics boosted as it unveils encouraging new preclinical DMD data https://www.proactiveinvestors.com/companies/news/108187/summit-therapeutics-boosted-as-it-unveils-encouraging-new-preclinical-dmd-data-108187.html Fri, 19 Jun 2015 12:49:00 -0400 https://www.proactiveinvestors.com/companies/news/108187/summit-therapeutics-boosted-as-it-unveils-encouraging-new-preclinical-dmd-data-108187.html Summit Therapeutics completes enrolment for DMD trial https://www.proactiveinvestors.com/companies/news/107958/summit-therapeutics-completes-enrolment-for-dmd-trial-107958.html Thu, 11 Jun 2015 15:27:00 -0400 https://www.proactiveinvestors.com/companies/news/107958/summit-therapeutics-completes-enrolment-for-dmd-trial-107958.html Summit targets key milestones over next twelve months https://www.proactiveinvestors.com/companies/news/68716/summit-targets-key-milestones-over-next-twelve-months-80053.html Wed, 06 May 2015 13:22:00 -0400 https://www.proactiveinvestors.com/companies/news/68716/summit-targets-key-milestones-over-next-twelve-months-80053.html Summit Therapeutics awarded US patent for CDI drug https://www.proactiveinvestors.com/companies/news/68573/summit-therapeutics-awarded-us-patent-for-cdi-drug-79869.html Thu, 30 Apr 2015 11:58:00 -0400 https://www.proactiveinvestors.com/companies/news/68573/summit-therapeutics-awarded-us-patent-for-cdi-drug-79869.html UPDATE - Summit NASDAQ listing begins as unveils US$34.2mln fundraise https://www.proactiveinvestors.com/companies/news/66811/update-summit-nasdaq-listing-begins-as-unveils-us342mln-fundraise--77948.html Drug development firm Summit reached another milestone on Thursday as it announced its NASDAQ listing in the US will begin today and unveiled a US$34.2mln fundraising alongside the IPO.

]]>
Thu, 05 Mar 2015 14:22:00 -0500 https://www.proactiveinvestors.com/companies/news/66811/update-summit-nasdaq-listing-begins-as-unveils-us342mln-fundraise--77948.html
UPDATE - Summit Therapeutics hires new director as pursues US listing https://www.proactiveinvestors.com/companies/news/66448/update-summit-therapeutics-hires-new-director-as-pursues-us-listing--77545.html Mon, 23 Feb 2015 09:15:00 -0500 https://www.proactiveinvestors.com/companies/news/66448/update-summit-therapeutics-hires-new-director-as-pursues-us-listing--77545.html Summit Therapeutics enrols first patients for DMD trial https://www.proactiveinvestors.com/companies/news/66391/summit-therapeutics-enrols-first-patients-for-dmd-trial-77487.html Fri, 20 Feb 2015 06:42:00 -0500 https://www.proactiveinvestors.com/companies/news/66391/summit-therapeutics-enrols-first-patients-for-dmd-trial-77487.html Summit shares climb as unveils US listing plans https://www.proactiveinvestors.com/companies/news/65820/summit-shares-climb-as-unveils-us-listing-plans-76845.html Shares in drug developer Summit jumped more than 10% on Monday as it told investors it continues to make progress on a number of fronts and unveiled plans to list on the NASDAQ exchange in the US.

]]>
Mon, 02 Feb 2015 09:47:00 -0500 https://www.proactiveinvestors.com/companies/news/65820/summit-shares-climb-as-unveils-us-listing-plans-76845.html
Summit unveils plans to list in USA; making progress on a "number of fronts" https://www.proactiveinvestors.com/companies/news/65802/summit-unveils-plans-to-list-in-usa-making-progress-on-a-number-of-fronts-76824.html Mon, 02 Feb 2015 06:20:00 -0500 https://www.proactiveinvestors.com/companies/news/65802/summit-unveils-plans-to-list-in-usa-making-progress-on-a-number-of-fronts-76824.html Summit shares climb as it mulls US listing https://www.proactiveinvestors.com/companies/news/64746/summit-shares-climb-as-it-mulls-us-listing-75629.html Fri, 19 Dec 2014 10:41:00 -0500 https://www.proactiveinvestors.com/companies/news/64746/summit-shares-climb-as-it-mulls-us-listing-75629.html Summit gets go-ahead for DMD dietary trial https://www.proactiveinvestors.com/companies/news/64448/summit-gets-go-ahead-for-dmd-dietary-trial-75288.html Thu, 11 Dec 2014 06:58:00 -0500 https://www.proactiveinvestors.com/companies/news/64448/summit-gets-go-ahead-for-dmd-dietary-trial-75288.html Summit Corp bids farewell to Jim Mellon https://www.proactiveinvestors.com/companies/news/64171/summit-corp-bids-farewell-to-jim-mellon-74982.html Wed, 03 Dec 2014 07:21:00 -0500 https://www.proactiveinvestors.com/companies/news/64171/summit-corp-bids-farewell-to-jim-mellon-74982.html BioMarin deal is positive for Summit, says N+1 Singer https://www.proactiveinvestors.com/companies/news/63931/biomarin-deal-is-positive-for-summit-says-n1-singer-74705.html Tue, 25 Nov 2014 11:04:00 -0500 https://www.proactiveinvestors.com/companies/news/63931/biomarin-deal-is-positive-for-summit-says-n1-singer-74705.html Summit Corporation's Pye on positive data for DMD treatment https://www.proactiveinvestors.com/companies/news/302761/summit-corporations-pye-on-positive-data-for-dmd-treatment-3156.html Fri, 10 Oct 2014 09:09:00 -0400 https://www.proactiveinvestors.com/companies/news/302761/summit-corporations-pye-on-positive-data-for-dmd-treatment-3156.html UPDATE - Summit Corp study points drug's potential to treat all Duchenne Muscular Dystrophy suffers https://www.proactiveinvestors.com/companies/news/62498/update-summit-corp-study-points-drugs-potential-to-treat-all-duchenne-muscular-dystrophy-suffers-73030.html Summit Corp said its breakthrough treatment Duchenne Muscular Dystrophy could help all sufferers of the muscle wasting disease. In the same release it also revealed some highly encouraging, but very early-stage data on a second-generation formulation of the drug.

]]>
Wed, 08 Oct 2014 10:07:00 -0400 https://www.proactiveinvestors.com/companies/news/62498/update-summit-corp-study-points-drugs-potential-to-treat-all-duchenne-muscular-dystrophy-suffers-73030.html
Summit to highlight second generation DMD treatment at key Berlin forum https://www.proactiveinvestors.com/companies/news/62497/summit-to-highlight-second-generation-dmd-treatment-at-key-berlin-forum-73029.html The new data illustrates how utrophin protein levels and improve muscle health are increased.

]]>
Wed, 08 Oct 2014 06:44:00 -0400 https://www.proactiveinvestors.com/companies/news/62497/summit-to-highlight-second-generation-dmd-treatment-at-key-berlin-forum-73029.html
Summit recruits new independent director https://www.proactiveinvestors.com/companies/news/61908/summit-recruits-new-independent-director-72411.html Fri, 19 Sep 2014 06:46:00 -0400 https://www.proactiveinvestors.com/companies/news/61908/summit-recruits-new-independent-director-72411.html UPDATE - Summit Corp says latest data points to efficacy of new antibiotic https://www.proactiveinvestors.com/companies/news/61492/update-summit-corp-says-latest-data-points-to-efficacy-of-new-antibiotic--71968.html Mon, 08 Sep 2014 12:19:00 -0400 https://www.proactiveinvestors.com/companies/news/61492/update-summit-corp-says-latest-data-points-to-efficacy-of-new-antibiotic--71968.html UPDATE - Summit plc looking forward to trials results https://www.proactiveinvestors.com/companies/news/61409/update-summit-plc-looking-forward-to-trials-results-71876.html Thu, 04 Sep 2014 12:36:00 -0400 https://www.proactiveinvestors.com/companies/news/61409/update-summit-plc-looking-forward-to-trials-results-71876.html Summit plc CEO pleased with drug development progress https://www.proactiveinvestors.com/companies/news/302659/summit-plc-ceo-pleased-with-drug-development-progress-3039.html Thu, 04 Sep 2014 10:44:00 -0400 https://www.proactiveinvestors.com/companies/news/302659/summit-plc-ceo-pleased-with-drug-development-progress-3039.html Summit Corporation climbs as CEO ups stake https://www.proactiveinvestors.com/companies/news/60415/summit-corporation-climbs-as-ceo-ups-stake-70819.html Wed, 30 Jul 2014 07:51:00 -0400 https://www.proactiveinvestors.com/companies/news/60415/summit-corporation-climbs-as-ceo-ups-stake-70819.html UPDATE - Summit Corp antibiotic could be fast-tracked under American initiative https://www.proactiveinvestors.com/companies/news/59826/update-summit-corp-antibiotic-could-be-fast-tracked-under-american-initiative-70207.html Summit Corp’s drug candidate for C. difficile infection has been accepted to a US initiative designed to speed up the development of new antibiotics. 

]]>
Wed, 09 Jul 2014 12:40:00 -0400 https://www.proactiveinvestors.com/companies/news/59826/update-summit-corp-antibiotic-could-be-fast-tracked-under-american-initiative-70207.html
Summit to unveil promising new results for its DMD treatment https://www.proactiveinvestors.com/companies/news/59756/summit-to-unveil-promising-new-results-for-its-dmd-treatment-70134.html Mon, 07 Jul 2014 06:59:00 -0400 https://www.proactiveinvestors.com/companies/news/59756/summit-to-unveil-promising-new-results-for-its-dmd-treatment-70134.html UPDATE - Summit reaches a major milestone as breakthrough antibiotic moves into phase-II trials https://www.proactiveinvestors.com/companies/news/59667/update-summit-reaches-a-major-milestone-as-breakthrough-antibiotic-moves-into-phase-ii-trials-70039.html Summit has reached a significant milestone in its development by taking its treatment for C. difficile infection into phase-II proof of concept trials.

]]>
Thu, 03 Jul 2014 09:19:00 -0400 https://www.proactiveinvestors.com/companies/news/59667/update-summit-reaches-a-major-milestone-as-breakthrough-antibiotic-moves-into-phase-ii-trials-70039.html
UPDATE - Summit appoints US-based chief financial officer https://www.proactiveinvestors.com/companies/news/59347/update-summit-appoints-us-based-chief-financial-officer-69703.html Mon, 23 Jun 2014 12:35:00 -0400 https://www.proactiveinvestors.com/companies/news/59347/update-summit-appoints-us-based-chief-financial-officer-69703.html Summit sets up shop at the heart of one of America's leading scientific communities https://www.proactiveinvestors.com/companies/news/59166/summit-sets-up-shop-at-the-heart-of-one-of-americas-leading-scientific-communities-69508.html Tue, 17 Jun 2014 06:51:00 -0400 https://www.proactiveinvestors.com/companies/news/59166/summit-sets-up-shop-at-the-heart-of-one-of-americas-leading-scientific-communities-69508.html Summit to restructure and consolidate share capital https://www.proactiveinvestors.com/companies/news/58778/summit-to-restructure-and-consolidate-share-capital--69098.html Tue, 03 Jun 2014 08:01:00 -0400 https://www.proactiveinvestors.com/companies/news/58778/summit-to-restructure-and-consolidate-share-capital--69098.html UPDATE - Summit adds investment banker to board https://www.proactiveinvestors.com/companies/news/58690/update-summit-adds-investment-banker-to-board-69002.html Fri, 30 May 2014 11:06:00 -0400 https://www.proactiveinvestors.com/companies/news/58690/update-summit-adds-investment-banker-to-board-69002.html Summit’s Pye talks about encouraging trial results https://www.proactiveinvestors.com/companies/news/302458/summits-pye-talks-about-encouraging-trial-results-2796.html Wed, 21 May 2014 13:44:00 -0400 https://www.proactiveinvestors.com/companies/news/302458/summits-pye-talks-about-encouraging-trial-results-2796.html UPDATE - Summit sees ‘unexpected’ success in DMD trial https://www.proactiveinvestors.com/companies/news/58420/update-summit-sees-unexpected-success-in-dmd-trial-68700.html Drug discovery group Summit said its potential breakthrough for Duchenne Muscular Dystrophy was safe and well tolerated as it reported patients saw a reduction in the enzyme associated with the wasting disease.

]]>
Wed, 21 May 2014 11:00:00 -0400 https://www.proactiveinvestors.com/companies/news/58420/update-summit-sees-unexpected-success-in-dmd-trial-68700.html
Summit study points to C.difficile drug's efficacy alongside frontline treatments https://www.proactiveinvestors.com/companies/news/58137/summit-study-points-to-cdifficile-drugs-efficacy-alongside-frontline-treatments-68407.html Drug developer Summit Corp said “exciting” results in non-clinical tests of SMT 19969 for C. difficile infection point to its potential efficacy alongside the two current frontline treatments.

]]>
Mon, 12 May 2014 06:03:00 -0400 https://www.proactiveinvestors.com/companies/news/58137/summit-study-points-to-cdifficile-drugs-efficacy-alongside-frontline-treatments-68407.html
Summit Corp financially well set to progress lead drugs https://www.proactiveinvestors.com/companies/news/57812/summit-corp-financially-well-set-to-progress-lead-drugs--68066.html Wed, 30 Apr 2014 06:59:00 -0400 https://www.proactiveinvestors.com/companies/news/57812/summit-corp-financially-well-set-to-progress-lead-drugs--68066.html Summit moves on to proof of concept with its C. difficile treatment https://www.proactiveinvestors.com/companies/news/302314/summit-moves-on-to-proof-of-concept-with-its-c-difficile-treatment--2627.html Wed, 19 Mar 2014 07:34:00 -0400 https://www.proactiveinvestors.com/companies/news/302314/summit-moves-on-to-proof-of-concept-with-its-c-difficile-treatment--2627.html Summit receives US green light for phase II studies on C.diff drug https://www.proactiveinvestors.com/companies/news/56584/summit-receives-us-green-light-for-phase-ii-studies-on-cdiff-drug--66771.html Drug developer Summit has been given the go ahead by American regulators to begin its phase-two, proof-of-concept study on a new-generation antibiotic for C. difficile infection.

]]>
Tue, 18 Mar 2014 06:48:00 -0400 https://www.proactiveinvestors.com/companies/news/56584/summit-receives-us-green-light-for-phase-ii-studies-on-cdiff-drug--66771.html
Summit primed for positive momentum - N+1 Singer https://www.proactiveinvestors.com/companies/news/56403/summit-primed-for-positive-momentum-n1-singer-66571.html Tue, 11 Mar 2014 12:08:00 -0400 https://www.proactiveinvestors.com/companies/news/56403/summit-primed-for-positive-momentum-n1-singer-66571.html UPDATE - Summit shareholder offer seven times oversubscribed https://www.proactiveinvestors.com/companies/news/56014/update-summit-shareholder-offer-seven-times-oversubscribed-66160.html Wed, 26 Feb 2014 14:04:00 -0500 https://www.proactiveinvestors.com/companies/news/56014/update-summit-shareholder-offer-seven-times-oversubscribed-66160.html Are European investors falling in love with biotech stocks? https://www.proactiveinvestors.com/companies/news/55679/are-european-investors-falling-in-love-with-biotech-stocks-65808.html America’s love affair with biotechnology is well charted. The pull is clear, but there are indications that European investors are starting to wake up to the potential of the sector and invest in biotechs.

]]>
Fri, 14 Feb 2014 12:33:00 -0500 https://www.proactiveinvestors.com/companies/news/55679/are-european-investors-falling-in-love-with-biotech-stocks-65808.html
Summit funded to do 'comprehensive job' on two drug programmes https://www.proactiveinvestors.com/companies/news/302232/summit-funded-to-do-comprehensive-job-on-two-drug-programmes--2537.html Wed, 12 Feb 2014 13:39:00 -0500 https://www.proactiveinvestors.com/companies/news/302232/summit-funded-to-do-comprehensive-job-on-two-drug-programmes--2537.html Summit funded through to 'value inflection point', says CEO https://www.proactiveinvestors.com/companies/news/55598/summit-funded-through-to-value-inflection-point-says-ceo-65743.html Glyn Edwards, chief executive of Summit Corp, said the drug developer will be fully funded to take its two key drugs through phase II clinical trials.

]]>
Wed, 12 Feb 2014 12:07:00 -0500 https://www.proactiveinvestors.com/companies/news/55598/summit-funded-through-to-value-inflection-point-says-ceo-65743.html
Summit set to raise up to £22mln to fund development of key drugs https://www.proactiveinvestors.com/companies/news/55597/summit-set-to-raise-up-to-22mln-to-fund-development-of-key-drugs-65719.html Summit has unveiled plans to raise up to £22mln to fund the development of a treatment for the muscle wasting disease Duchenne Muscular Dystrophy and an antibiotic to combat C. difficile infections.

]]>
Wed, 12 Feb 2014 06:26:00 -0500 https://www.proactiveinvestors.com/companies/news/55597/summit-set-to-raise-up-to-22mln-to-fund-development-of-key-drugs-65719.html
Sarepta DMD trial results buoy Summit https://www.proactiveinvestors.com/companies/news/54876/sarepta-dmd-trial-results-buoy-summit-64929.html The latest trial results from America’s Sarepta Therapeutics bode well for AIM-listed Summit

]]>
Thu, 16 Jan 2014 15:37:00 -0500 https://www.proactiveinvestors.com/companies/news/54876/sarepta-dmd-trial-results-buoy-summit-64929.html
Large-cap biotechs to blaze a trail https://www.proactiveinvestors.com/companies/news/54454/large-cap-biotechs-to-blaze-a-trail-64488.html It promises to be a bumper 12 months for the global biotechnology industry with the big blue-chip research firms continuing to deliver. Globally, biotech has been the top performing sector for the past three years, meaning investors have been rewarded for all those lean years before the upswing. 

]]>
Mon, 30 Dec 2013 08:01:00 -0500 https://www.proactiveinvestors.com/companies/news/54454/large-cap-biotechs-to-blaze-a-trail-64488.html
UPDATE - Summit trial assesses 12 patients with rare muscle wasting disease https://www.proactiveinvestors.com/companies/news/53971/update-summit-trial-assesses-12-patients-with-rare-muscle-wasting-disease-63991.html Summit has treated its first patient suffering from the fatal muscle wasting disease Duchenne Muscular Dystrophy as part of phase-1b clinical trial of SMT C1100, it was revealed on Monday.

]]>
Mon, 09 Dec 2013 09:26:00 -0500 https://www.proactiveinvestors.com/companies/news/53971/update-summit-trial-assesses-12-patients-with-rare-muscle-wasting-disease-63991.html
UPDATE - Summit seals exclusive deal with Oxford University that underpins its DMD programme https://www.proactiveinvestors.com/companies/news/53559/update-summit-seals-exclusive-deal-with-oxford-university-that-underpins-its-dmd-programme-63533.html Drug developer Summit has acquired the exclusive rights to a pipeline of new utrophin modulators, the technology at the core of its treatment for Duchenne Muscular Dystrophy.

]]>
Mon, 25 Nov 2013 15:27:00 -0500 https://www.proactiveinvestors.com/companies/news/53559/update-summit-seals-exclusive-deal-with-oxford-university-that-underpins-its-dmd-programme-63533.html
Summit's strong prospects prompt broker upgrade https://www.proactiveinvestors.com/companies/news/53372/summits-strong-prospects-prompt-broker-upgrade-63343.html Mon, 18 Nov 2013 11:34:00 -0500 https://www.proactiveinvestors.com/companies/news/53372/summits-strong-prospects-prompt-broker-upgrade-63343.html Summit secures charity funding https://www.proactiveinvestors.com/companies/news/52969/summit-secures-charity-funding-62893.html Tue, 05 Nov 2013 06:57:00 -0500 https://www.proactiveinvestors.com/companies/news/52969/summit-secures-charity-funding-62893.html Summit gets go-ahead to start patient trials of DMD drug https://www.proactiveinvestors.com/companies/news/52882/summit-gets-go-ahead-to-start-patient-trials-of-dmd-drug-62795.html "The start of the first patient trial of SMT C1100 is an important moment for the whole DMD community," said Professor Francesco Muntoni, paediatric neurologist at Great Ormond Street Hospital. The professor will be the chief investigator on the trial.

]]>
Fri, 01 Nov 2013 06:25:00 -0400 https://www.proactiveinvestors.com/companies/news/52882/summit-gets-go-ahead-to-start-patient-trials-of-dmd-drug-62795.html
Summit to present at California medical congress https://www.proactiveinvestors.com/companies/news/51866/summit-to-present-at-california-medical-congress-61643.html Mon, 30 Sep 2013 13:05:00 -0400 https://www.proactiveinvestors.com/companies/news/51866/summit-to-present-at-california-medical-congress-61643.html Summit presentations points to antibiotic's potential https://www.proactiveinvestors.com/companies/news/51244/summit-presentations-points-to-antibiotics-potential--60941.html Drug developer Summit is presenting data that points to the huge potential of its antibiotic in tackling the C.difficile superbug.

]]>
Wed, 11 Sep 2013 06:33:00 -0400 https://www.proactiveinvestors.com/companies/news/51244/summit-presentations-points-to-antibiotics-potential--60941.html
Summit to present C difficile data at Denver conference https://www.proactiveinvestors.com/companies/news/51066/summit-to-present-c-difficile-data-at-denver-conference-60737.html Wed, 04 Sep 2013 12:14:00 -0400 https://www.proactiveinvestors.com/companies/news/51066/summit-to-present-c-difficile-data-at-denver-conference-60737.html UPDATE - Summit receives cornerstone patent in US for muscular dystrophy drug https://www.proactiveinvestors.com/companies/news/50808/update-summit-receives-cornerstone-patent-in-us-for-muscular-dystrophy-drug--60449.html The drug development group Summit has been issued a composition of matter patent that covers its discovery SMT C1100 for use in the treatment of the fatal muscle wasting disease Duchenne Muscular Dystrophy.

]]>
Wed, 28 Aug 2013 12:17:00 -0400 https://www.proactiveinvestors.com/companies/news/50808/update-summit-receives-cornerstone-patent-in-us-for-muscular-dystrophy-drug--60449.html
Summit entering exciting stage of its development https://www.proactiveinvestors.com/companies/news/50660/summit-entering-exciting-stage-of-its-development-60281.html Thu, 22 Aug 2013 06:49:00 -0400 https://www.proactiveinvestors.com/companies/news/50660/summit-entering-exciting-stage-of-its-development-60281.html Summit muscular dystrophy drug receives US protection for use in tandem with other treatments https://www.proactiveinvestors.com/companies/news/50230/summit-muscular-dystrophy-drug-receives-us-protection-for-use-in-tandem-with-other-treatments-59794.html Summit has revealed it has been granted an important US patent that covers the use of its drug candidate SMT C1100 in combination with existing treatments for Duchenne Muscular Dystrophy.

]]>
Wed, 07 Aug 2013 13:35:00 -0400 https://www.proactiveinvestors.com/companies/news/50230/summit-muscular-dystrophy-drug-receives-us-protection-for-use-in-tandem-with-other-treatments-59794.html
Additional US patent is important for the company, CEO says https://www.proactiveinvestors.com/companies/news/301899/additional-us-patent-is-important-for-the-company-ceo-says--2134.html Wed, 07 Aug 2013 13:22:00 -0400 https://www.proactiveinvestors.com/companies/news/301899/additional-us-patent-is-important-for-the-company-ceo-says--2134.html Summit gets £2.4mln injection https://www.proactiveinvestors.com/companies/news/50022/summit-gets-24mln-injection-59556.html Summit has been awarded a £2.4mln grant from the UK Biomedical Catalyst Fund to support the clinical development of its drug for Duchenne Muscular Dystrophy, the fatal muscle wasting disease

]]>
Wed, 31 Jul 2013 06:35:00 -0400 https://www.proactiveinvestors.com/companies/news/50022/summit-gets-24mln-injection-59556.html
Summit receives financial backing to find a treatment for killer disease https://www.proactiveinvestors.com/companies/news/49651/summit-receives-financial-backing-to-find-a-treatment-for-killer-disease-59130.html Drug developer Summit has received further financial support for its quest to find a treatment for Duchenne Muscular Dystrophy, the rare muscle wasting disease that affects boys. A total of A$1.25mln has been pledged by the Australian DMD foundation, Save Our Sons.

]]>
Thu, 18 Jul 2013 06:40:00 -0400 https://www.proactiveinvestors.com/companies/news/49651/summit-receives-financial-backing-to-find-a-treatment-for-killer-disease-59130.html
Summit tops up recent placing https://www.proactiveinvestors.com/companies/news/49583/summit-tops-up-recent-placing-59045.html Tue, 16 Jul 2013 09:38:00 -0400 https://www.proactiveinvestors.com/companies/news/49583/summit-tops-up-recent-placing-59045.html Summit fund-raise attracts the specialist pharma investors https://www.proactiveinvestors.com/companies/news/49227/summit-fund-raise-attracts-the-specialist-pharma-investors-58641.html "Healthcare specialists see our programmes as huge opportunities and really wanted to get a piece of them,” chief executive Glyn Edwards told Proactive Investors.

]]>
Wed, 03 Jul 2013 10:58:00 -0400 https://www.proactiveinvestors.com/companies/news/49227/summit-fund-raise-attracts-the-specialist-pharma-investors-58641.html
Summit: Investors endorse drug developer's progress with £5.5mln cash call done at a premium https://www.proactiveinvestors.com/companies/news/49208/summit-investors-endorse-drug-developers-progress-with-55mln-cash-call-done-at-a-premium-58622.html Drug developer Summit Corp is raising up to £5.5mln via a placing and open offer of stock at a near 18% premium to last night’s closing share price. The cash injection will be used to fund the development of its potentially breakthrough treatment of Duchenne Muscular Dystrophy, the fatal muscle wasting disease that affects boys.

]]>
Wed, 03 Jul 2013 06:21:00 -0400 https://www.proactiveinvestors.com/companies/news/49208/summit-investors-endorse-drug-developers-progress-with-55mln-cash-call-done-at-a-premium-58622.html
Summit Group receives first payment from Wellcome Trust https://www.proactiveinvestors.com/companies/news/48718/summit-group-receives-first-payment-from-wellcome-trust-58055.html Drug developer Summit said the successful completion of phase I clinical trials on SMT 19969, its antibiotic for C.difficile, has triggered a £740,000 payment from the Wellcome Trust medical charity.

]]>
Mon, 17 Jun 2013 10:13:00 -0400 https://www.proactiveinvestors.com/companies/news/48718/summit-group-receives-first-payment-from-wellcome-trust-58055.html
Summit CEO says CMO appointment a "great catch" for the Co. https://www.proactiveinvestors.com/companies/news/301827/summit-ceo-says-cmo-appointment-a-great-catch-for-the-co--2046.html Fri, 14 Jun 2013 09:23:00 -0400 https://www.proactiveinvestors.com/companies/news/301827/summit-ceo-says-cmo-appointment-a-great-catch-for-the-co--2046.html Summit appoints former Pfizer man as chief medical officer https://www.proactiveinvestors.com/companies/news/48595/summit-appoints-former-pfizer-man-as-chief-medical-officer-57906.html The drug discovery group Summit has appointed one of Europe's leading experts in translational medicine a chief medical officer. He is Dr David Roblin, who has held senior roles at industry giants Pfizer and Bayer, where he helped develop and launch new treatments in areas including infectious and metabolic diseases.

]]>
Wed, 12 Jun 2013 07:06:00 -0400 https://www.proactiveinvestors.com/companies/news/48595/summit-appoints-former-pfizer-man-as-chief-medical-officer-57906.html
Summit Corp names experienced pharma executive as new chairman https://www.proactiveinvestors.com/companies/news/48476/summit-corp-names-experienced-pharma-executive-as-new-chairman-57769.html Fri, 07 Jun 2013 06:06:00 -0400 https://www.proactiveinvestors.com/companies/news/48476/summit-corp-names-experienced-pharma-executive-as-new-chairman-57769.html Summit chief hails "fantastic" result from antibiotic trial https://www.proactiveinvestors.com/companies/news/47090/summit-chief-hails-fantastic-result-from-antibiotic-trial-56168.html Summit chief executive Glyn Edwards has described as “fantastic” the results from early clinical trials of its antibiotic for the hospital super-bug C.difficile. The phase I study on 56 healthy patients revealed SMT 19969 is both safe and well tolerated in the doses that would be required to treat patients.

]]>
Wed, 24 Apr 2013 11:14:00 -0400 https://www.proactiveinvestors.com/companies/news/47090/summit-chief-hails-fantastic-result-from-antibiotic-trial-56168.html
Summit antibiotic reveals encouraging early potential https://www.proactiveinvestors.com/companies/news/47093/summit-antibiotic-reveals-encouraging-early-potential--56155.html Summit has unveiled encouraging early results from clinical trials on the antibiotic it is developing for C.difficile. The phase I study on 56 healthy patients revealed SMT 19969 is both safe and well tolerated in the doses that would be required to treat patients.

]]>
Wed, 24 Apr 2013 06:32:00 -0400 https://www.proactiveinvestors.com/companies/news/47093/summit-antibiotic-reveals-encouraging-early-potential--56155.html
Summit chief Edwards says a lot more clinical progress is coming https://www.proactiveinvestors.com/companies/news/46717/summit-chief-edwards-says-a-lot-more-clinical-progress-is-coming-55723.html “We’ve really achieved a huge amount with a complete refocusing of the business and the delivery of some fantastic data for our DMD programme,” chief executive Glyn Edwards told Proactive.

]]>
Thu, 11 Apr 2013 13:58:00 -0400 https://www.proactiveinvestors.com/companies/news/46717/summit-chief-edwards-says-a-lot-more-clinical-progress-is-coming-55723.html
Summit results chart a year of significant progress https://www.proactiveinvestors.com/companies/news/46698/summit-results-chart-a-year-of-significant-progress-55701.html Thu, 11 Apr 2013 07:10:00 -0400 https://www.proactiveinvestors.com/companies/news/46698/summit-results-chart-a-year-of-significant-progress-55701.html First patient studies represent "significant acceleration" of plans, says Edwards https://www.proactiveinvestors.com/companies/news/46136/first-patient-studies-represent-significant-acceleration-of-plans-says-edwards-55048.html The first patient studies of Summit's treatment for Duchenne Muscular Dystrophy represents a "significant acceleration" in the development programme, says CEO.

]]>
Thu, 21 Mar 2013 15:45:00 -0400 https://www.proactiveinvestors.com/companies/news/46136/first-patient-studies-represent-significant-acceleration-of-plans-says-edwards-55048.html
Summit outlines next steps in development of potentially breakthrough treatment https://www.proactiveinvestors.com/companies/news/46104/summit-outlines-next-steps-in-development-of-potentially-breakthrough-treatment-55011.html The drug discovery group Summit has outlined its plans to further develop a potentially breakthrough treatment for muscle wasting disorder Duchenne Muscular Dystrophy.

]]>
Thu, 21 Mar 2013 06:31:00 -0400 https://www.proactiveinvestors.com/companies/news/46104/summit-outlines-next-steps-in-development-of-potentially-breakthrough-treatment-55011.html
UPDATE: Summit reveals encouraging early data for potential Alzheimer’s treatment https://www.proactiveinvestors.com/companies/news/45763/update-summit-reveals-encouraging-early-data-for-potential-alzheimers-treatment-54610.html Drug developer Summit has unveiled encouraging new data on its OGA inhibitor emanating from a pre-clinical study of efficacy in Alzheimer’s and related diseases.

]]>
Mon, 11 Mar 2013 13:29:00 -0400 https://www.proactiveinvestors.com/companies/news/45763/update-summit-reveals-encouraging-early-data-for-potential-alzheimers-treatment-54610.html
Summit draft in six experts to support its Duchenne Muscular Dystrophy programme https://www.proactiveinvestors.com/companies/news/44947/summit-draft-in-six-experts-to-support-its-duchenne-muscular-dystrophy-programme-53628.html Summit Corporation this morning unveiled a scientific advisory board to support its Duchenne Muscular Dystrophy programme. In all, six experts in the area of DMD and neuromuscular diseases have been drafted in by chief executive Glynn Edwards and his team.

]]>
Wed, 13 Feb 2013 06:59:00 -0500 https://www.proactiveinvestors.com/companies/news/44947/summit-draft-in-six-experts-to-support-its-duchenne-muscular-dystrophy-programme-53628.html
UPDATE: Summit teams up with Children's National Medical Center https://www.proactiveinvestors.com/companies/news/44727/update-summit-teams-up-with-childrens-national-medical-center-53369.html Summit has received a boost to its Duchenne Muscular Dystrophy (DMD) project with a charitable foundation agreeing to fund part of its testing programme.

]]>
Wed, 06 Feb 2013 12:30:00 -0500 https://www.proactiveinvestors.com/companies/news/44727/update-summit-teams-up-with-childrens-national-medical-center-53369.html
Summit teams up with Children's National Medical Center https://www.proactiveinvestors.com/companies/news/44712/summit-teams-up-with-childrens-national-medical-center-53353.html Wed, 06 Feb 2013 06:53:00 -0500 https://www.proactiveinvestors.com/companies/news/44712/summit-teams-up-with-childrens-national-medical-center-53353.html UPDATE: Summit appoints Mellon and Armstrong to the board https://www.proactiveinvestors.com/companies/news/42470/update-summit-appoints-mellon-and-armstrong-to-the-board-50687.html Drug discovery group Summit said the entrepreneur and investor Jim Mellon is one of two new non-executive directors that have been appointed to the board.

]]>
Thu, 22 Nov 2012 10:37:00 -0500 https://www.proactiveinvestors.com/companies/news/42470/update-summit-appoints-mellon-and-armstrong-to-the-board-50687.html
Summit Investor Presentation - 22nd November 2012 https://www.proactiveinvestors.com/companies/news/301408/summit-investor-presentation-22nd-november-2012-1460.html Thu, 22 Nov 2012 08:24:00 -0500 https://www.proactiveinvestors.com/companies/news/301408/summit-investor-presentation-22nd-november-2012-1460.html Summit appoints Mellon and Armstrong to the board https://www.proactiveinvestors.com/companies/news/42459/summit-appoints-mellon-and-armstrong-to-the-board-50672.html  

Drug discovery group Summit (LON:SUMM) said the entrepreneur and investor Jim Mellon is one of two new non-executive directors that have been appointed to the board.

The other is Frank Armstrong, a medically qualified doctor who has worked at board level on a number of pharmaceutical companies.

 

 

]]>
Thu, 22 Nov 2012 07:06:00 -0500 https://www.proactiveinvestors.com/companies/news/42459/summit-appoints-mellon-and-armstrong-to-the-board-50672.html
The Real Good Food Company, Advanced Computer Software, Summit and TyraTech to present at Proactive One2One forum https://www.proactiveinvestors.com/companies/news/42051/the-real-good-food-company-advanced-computer-software-summit-and-tyratech-to-present-at-proactive-one2one-forum--50148.html Proactive Investors is serving up an eclectic mix of companies at its next One2One forum on Thursday, November 22.

]]>
Fri, 09 Nov 2012 16:00:00 -0500 https://www.proactiveinvestors.com/companies/news/42051/the-real-good-food-company-advanced-computer-software-summit-and-tyratech-to-present-at-proactive-one2one-forum--50148.html
Summit CEO "really excited" about prospects, but share price "woefully low" https://www.proactiveinvestors.com/companies/news/301385/summit-ceo-really-excited-about-prospects-but-share-price-woefully-low-1434.html Fri, 09 Nov 2012 08:54:00 -0500 https://www.proactiveinvestors.com/companies/news/301385/summit-ceo-really-excited-about-prospects-but-share-price-woefully-low-1434.html Summit shares surge following latest, highly encouraging update on DMD drug study https://www.proactiveinvestors.com/companies/news/41962/summit-shares-surge-following-latest-highly-encouraging-update-on-dmd-drug-study-50043.html Shares in Summit rose 13 per cent after the drug developer unveiled highly encouraging results from the repeat dosing of its SMT C1100 treatment for Duchenne Muscular Dystrophy. 

]]>
Wed, 07 Nov 2012 11:15:00 -0500 https://www.proactiveinvestors.com/companies/news/41962/summit-shares-surge-following-latest-highly-encouraging-update-on-dmd-drug-study-50043.html
Summit unveils highly encouraging results from repeat dosing study on DMD drug https://www.proactiveinvestors.com/companies/news/41946/summit-unveils-highly-encouraging-results-from-repeat-dosing-study-on-dmd-drug-50027.html Summit this morning unveiled highly encouraging results from repeat dosing of its SMT C1100 for Duchenne Muscular Dystrophy that support its transition into the next phase of clinical studies

]]>
Wed, 07 Nov 2012 06:12:00 -0500 https://www.proactiveinvestors.com/companies/news/41946/summit-unveils-highly-encouraging-results-from-repeat-dosing-study-on-dmd-drug-50027.html
UPDATE: Summit Corp begins dosing in Phase 1 clinical trial https://www.proactiveinvestors.com/companies/news/41739/update-summit-corp-begins-dosing-in-phase-1-clinical-trial-49768.html

Drug discovery group Summit has begun the dosing phase of a Phase 1 clinical trial of a potential antibiotic treatment for C.Difficile infections. 

]]>
Wed, 31 Oct 2012 13:28:00 -0400 https://www.proactiveinvestors.com/companies/news/41739/update-summit-corp-begins-dosing-in-phase-1-clinical-trial-49768.html
Summit Corp begins dosing in Phase 1 clinical trial https://www.proactiveinvestors.com/companies/news/41716/summit-corp-begins-dosing-in-phase-1-clinical-trial-49743.html Wed, 31 Oct 2012 06:23:00 -0400 https://www.proactiveinvestors.com/companies/news/41716/summit-corp-begins-dosing-in-phase-1-clinical-trial-49743.html Summit boss says Wellcome Trust deal provides "huge validation" of C.diff programme https://www.proactiveinvestors.com/companies/news/41447/summit-boss-says-wellcome-trust-deal-provides-huge-validation-of-cdiff-programme-49424.html Summit’s partnership with medical charity Wellcome Trust provides “huge validation” of the drug developer’s C.difficile programme as well as delivering a major source of non-dilutive financing, says boss Glyn Edwards.

]]>
Mon, 22 Oct 2012 10:32:00 -0400 https://www.proactiveinvestors.com/companies/news/41447/summit-boss-says-wellcome-trust-deal-provides-huge-validation-of-cdiff-programme-49424.html
Summit agrees C.difficile funding deal with Wellcome Trust worth up to £4m https://www.proactiveinvestors.com/companies/news/41428/summit-agrees-cdifficile-funding-deal-with-wellcome-trust-worth-up-to-4m-49405.html Summit said this morning it is extending its partnership with the Wellcome Trust after receiving an award worth up to £4 million that will support the development of its antibiotic for C.difficile.

]]>
Mon, 22 Oct 2012 06:07:00 -0400 https://www.proactiveinvestors.com/companies/news/41428/summit-agrees-cdifficile-funding-deal-with-wellcome-trust-worth-up-to-4m-49405.html
Summit trial removes a lot of uncertainty over DMD drug, says CEO https://www.proactiveinvestors.com/companies/news/41077/summit-trial-removes-a-lot-of-uncertainty-over-dmd-drug-says-ceo-48971.html Summit's potentially breakthrough treatment for Duchenne Muscular Dystrophy has cleared a “massive hurdle that has removed a lot of uncertainty”, said chief executive Glyn Edwards. 

]]>
Wed, 10 Oct 2012 14:53:00 -0400 https://www.proactiveinvestors.com/companies/news/41077/summit-trial-removes-a-lot-of-uncertainty-over-dmd-drug-says-ceo-48971.html
UPDATE: Summit shares soar as it comfortably navigates phase I trial https://www.proactiveinvestors.com/companies/news/41069/update-summit-shares-soar-as-it-comfortably-navigates-phase-i-trial--48962.html Shares in Summit soared over 20% in early deals after the drug developer unveiled positive phase I trial results for its potentially breakthrough treatment for the fatal muscle wasting disease Duchenne Muscular Dystrophy (DMD).

]]>
Wed, 10 Oct 2012 07:59:00 -0400 https://www.proactiveinvestors.com/companies/news/41069/update-summit-shares-soar-as-it-comfortably-navigates-phase-i-trial--48962.html
Summit data provides encouragement as co comfortably navigates phase I trial https://www.proactiveinvestors.com/companies/news/41060/summit-data-provides-encouragement-as-co-comfortably-navigates-phase-i-trial-48953.html Summit Corporation (LON:SUMM) this morning unveiled positive phase I trial results for its potentially breakthrough treatment for the fatal muscle wasting disease Duchenne Muscular Dystrophy.

]]>
Wed, 10 Oct 2012 06:09:00 -0400 https://www.proactiveinvestors.com/companies/news/41060/summit-data-provides-encouragement-as-co-comfortably-navigates-phase-i-trial-48953.html
UPDATE: Summit c.diff drug to go in phase I trials; pre-clinical data very encouraging https://www.proactiveinvestors.com/companies/news/40597/update-summit-cdiff-drug-to-go-in-phase-i-trials-pre-clinical-data-very-encouraging-48409.html Shares in the company rose by as much as 7 per cent in early trade, but succumbed to a bout of profit-taking. At 2pm the stock was changing hands for 3.6 pence, down 0.03 pence on the day

]]>
Tue, 25 Sep 2012 12:52:00 -0400 https://www.proactiveinvestors.com/companies/news/40597/update-summit-cdiff-drug-to-go-in-phase-i-trials-pre-clinical-data-very-encouraging-48409.html
Summit c.diff drug to go in phase I trials; pre-clinical data very encouraging https://www.proactiveinvestors.com/companies/news/40579/summit-cdiff-drug-to-go-in-phase-i-trials-pre-clinical-data-very-encouraging-48388.html Summit Group said it has been given the go ahead to take its c.difficile drug candidate into phase I clinical trials as it released early stage data that give a hint to its huge potential.

]]>
Tue, 25 Sep 2012 06:34:00 -0400 https://www.proactiveinvestors.com/companies/news/40579/summit-cdiff-drug-to-go-in-phase-i-trials-pre-clinical-data-very-encouraging-48388.html
Summit chief says Bristol-Myers partnership "a fantastic deal" https://www.proactiveinvestors.com/companies/news/40242/summit-chief-says-bristol-myers-partnership-a-fantastic-deal-48009.html Shares in Summit Corp consolidated on the strong gains made yesterday as investors digested the huge potential of the drug developer’s tie-up with one of the world’s largest pharmaceuticals companies.

]]>
Wed, 12 Sep 2012 10:56:00 -0400 https://www.proactiveinvestors.com/companies/news/40242/summit-chief-says-bristol-myers-partnership-a-fantastic-deal-48009.html
Summit scales the heights after Bristol-Myers deal https://www.proactiveinvestors.com/companies/news/40191/summit-scales-the-heights-after-bristol-myers-deal-47955.html Shares in Summit Corporation rose more than 33 per cent in early trade after it unveiled a collaboration with one of the world’s largest pharmaceuticals companies.

 

 

]]>
Tue, 11 Sep 2012 13:49:00 -0400 https://www.proactiveinvestors.com/companies/news/40191/summit-scales-the-heights-after-bristol-myers-deal-47955.html
Summit inks breakthrough Seglin deal with Bristol-Myers Squibb https://www.proactiveinvestors.com/companies/news/40195/summit-inks-breakthrough-seglin-deal-with-bristol-myers-squibb-47959.html Tue, 11 Sep 2012 06:08:00 -0400 https://www.proactiveinvestors.com/companies/news/40195/summit-inks-breakthrough-seglin-deal-with-bristol-myers-squibb-47959.html Summit inks breakthrough Seglin deal with Bristol-Myers Squibb https://www.proactiveinvestors.com/companies/news/40171/summit-inks-breakthrough-seglin-deal-with-bristol-myers-squibb-47935.html  

Summit Corp this morning unveiled a collaboration with one of the world’s largest pharmaceuticals companies that could eventually be worth US$30 million per product in research, development and regulatory milestone payments.

 

]]>
Tue, 11 Sep 2012 06:05:00 -0400 https://www.proactiveinvestors.com/companies/news/40171/summit-inks-breakthrough-seglin-deal-with-bristol-myers-squibb-47935.html
Summit chief says new focus will boost shareholder value https://www.proactiveinvestors.com/companies/news/40043/summit-chief-says-new-focus-will-boost-shareholder-value-47768.html “For us this is an extremely important move,” Glyn Edwards told Proactive Investors. 

]]>
Thu, 06 Sep 2012 14:33:00 -0400 https://www.proactiveinvestors.com/companies/news/40043/summit-chief-says-new-focus-will-boost-shareholder-value-47768.html
Summit Corp reveals new sharper strategic focus https://www.proactiveinvestors.com/companies/news/40009/summit-corp-reveals-new-sharper-strategic-focus-47733.html The biotechnology group will devote its attention to the development of two drugs – one for Duchenne Muscular Dystrophy, the other for C. difficile infections.

]]>
Thu, 06 Sep 2012 06:07:00 -0400 https://www.proactiveinvestors.com/companies/news/40009/summit-corp-reveals-new-sharper-strategic-focus-47733.html
Summit achieves milestone payment trigger for DMD treatment https://www.proactiveinvestors.com/companies/news/36831/summit-achieves-milestone-payment-trigger-for-dmd-treatment-44028.html Tue, 12 Jun 2012 12:12:00 -0400 https://www.proactiveinvestors.com/companies/news/36831/summit-achieves-milestone-payment-trigger-for-dmd-treatment-44028.html Summit Corporation chief says this year is all about data and deals https://www.proactiveinvestors.com/companies/news/36766/summit-corporation-chief-says-this-year-is-all-about-data-and-deals-43959.html The next year is all about “data and deals” for Summit Corporation, according to Glyn Edwards, the AIM-listed biotech’s new chief executive. The data relates to early clinical studies and pre-clinical work to be carried out this year and into early next.


 

]]>
Mon, 11 Jun 2012 10:23:00 -0400 https://www.proactiveinvestors.com/companies/news/36766/summit-corporation-chief-says-this-year-is-all-about-data-and-deals-43959.html
Summit Corporation shares up as starts Phase 1 trials of SMT C1100 https://www.proactiveinvestors.com/companies/news/36267/summit-corporation-shares-up-as-starts-phase-1-trials-of-smt-c1100-43339.html Fri, 25 May 2012 11:55:00 -0400 https://www.proactiveinvestors.com/companies/news/36267/summit-corporation-shares-up-as-starts-phase-1-trials-of-smt-c1100-43339.html Summit Corp enters an “intense period of development” https://www.proactiveinvestors.com/companies/news/301142/summit-corp-enters-an-intense-period-of-development-1146.html Fri, 11 May 2012 08:43:00 -0400 https://www.proactiveinvestors.com/companies/news/301142/summit-corp-enters-an-intense-period-of-development-1146.html Summit Corporation shares surge as gets green light for phase I trials of Duchenne Muscular Dystrophy drug https://www.proactiveinvestors.com/companies/news/35102/summit-corporation-shares-surge-as-gets-green-light-for-phase-i-trials-of-duchenne-muscular-dystrophy-drug-41891.html Chief executive Glyn Edwards told Proactive Investors it was an "important milestone" for the company. The phase I study will test the safety and tolerability of an oral formulation of Summit’s SMT C1100 

 

]]>
Tue, 24 Apr 2012 15:02:00 -0400 https://www.proactiveinvestors.com/companies/news/35102/summit-corporation-shares-surge-as-gets-green-light-for-phase-i-trials-of-duchenne-muscular-dystrophy-drug-41891.html
Summit Corporation gets green light for human trials of Duchenne Muscular Dystrophy drug https://www.proactiveinvestors.com/companies/news/35073/summit-corporation-gets-green-light-for-human-trials-of-duchenne-muscular-dystrophy-drug-41861.html The drug discovery group Summit Corporation (LON:SUMM) has received the green light for human trials of its potentially breakthrough treatment for Duchenne Muscular Dystrophy.

]]>
Tue, 24 Apr 2012 07:09:00 -0400 https://www.proactiveinvestors.com/companies/news/35073/summit-corporation-gets-green-light-for-human-trials-of-duchenne-muscular-dystrophy-drug-41861.html
Summit Corp reports positive data from Alzheimer’s drug studies, shares up https://www.proactiveinvestors.com/companies/news/33434/summit-corp-reports-positive-data-from-alzheimers-drug-studies-shares-up--39822.html Compounds it is developing to combat Alzheimer’s have shown the ability to penetrate the Blood Brain Barrier, a major obstacle for any drugs group developing treatments that have to act in the brain.

 

]]>
Tue, 06 Mar 2012 08:27:00 -0500 https://www.proactiveinvestors.com/companies/news/33434/summit-corp-reports-positive-data-from-alzheimers-drug-studies-shares-up--39822.html
Summit Corp still a ‘buy’ at Hybridan, target price 30 pence/share https://www.proactiveinvestors.com/companies/news/33039/summit-corp-still-a-buy-at-hybridan-target-price-30-penceshare-39339.html Thu, 23 Feb 2012 10:38:00 -0500 https://www.proactiveinvestors.com/companies/news/33039/summit-corp-still-a-buy-at-hybridan-target-price-30-penceshare-39339.html Summit Corporation to submit trial application for Duchenne Muscular Dystrophy drug - UPDATE https://www.proactiveinvestors.com/companies/news/32729/summit-corporation-to-submit-trial-application-for-duchenne-muscular-dystrophydrug-update-38965.html Tue, 14 Feb 2012 11:22:00 -0500 https://www.proactiveinvestors.com/companies/news/32729/summit-corporation-to-submit-trial-application-for-duchenne-muscular-dystrophydrug-update-38965.html Summit Corporation to submit trial application for anti-DMD drug in Q1, results expected in Q3 https://www.proactiveinvestors.com/companies/news/32723/summit-corporation-to-submit-trial-application-for-anti-dmd-drug-in-q1-results-expected-in-q3-38959.html Tue, 14 Feb 2012 08:03:00 -0500 https://www.proactiveinvestors.com/companies/news/32723/summit-corporation-to-submit-trial-application-for-anti-dmd-drug-in-q1-results-expected-in-q3-38959.html Summit Corp to present Alzheimer’s research data at Paris conference https://www.proactiveinvestors.com/companies/news/25823/summit-corp-to-present-alzheimers-research-data-at-paris-conference-30825.html Tue, 19 Jul 2011 08:06:00 -0400 https://www.proactiveinvestors.com/companies/news/25823/summit-corp-to-present-alzheimers-research-data-at-paris-conference-30825.html Summit Corporation to sell Zebrafish business to Evotech AG https://www.proactiveinvestors.com/companies/news/3960/summit-corporation-to-sell-zebrafish-business-to-evotech-ag-5537.html Thu, 07 May 2009 10:28:00 -0400 https://www.proactiveinvestors.com/companies/news/3960/summit-corporation-to-sell-zebrafish-business-to-evotech-ag-5537.html